British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma by Banks, M. (Matthew) et al.
  1Banks M, et al. Gut 2019;0:1–31. doi:10.1136/gutjnl-2018-318126
Guidelines
British Society of Gastroenterology guidelines on the 
diagnosis and management of patients at risk of 
gastric adenocarcinoma
Matthew Banks,  1,2 David Graham,1,3 Marnix Jansen,  4 Takuji Gotoda,5 Sergio Coda,6 
Massimiliano di Pietro,7,8 Noriya Uedo,9 Pradeep Bhandari,10 D Mark Pritchard,11 
Ernst J Kuipers,12 Manuel Rodriguez-Justo,4 Marco R Novelli,4 Krish Ragunath,13 
Neil Shepherd,14 Mario Dinis-Ribeiro15
To cite: Banks M, Graham D, 
Jansen M, et al. Gut Epub 
ahead of print: [please 
include Day Month Year]. 
doi:10.1136/
gutjnl-2018-318126
For numbered affiliations see 
end of article.
Correspondence to
Dr Matthew Banks, University 
College London Hospital, 
University College London 
Hospitals NHS Foundation Trust, 
London NW12PG, UK;  
 matthew. banks2@ nhs. net
Received 16 December 2018
Revised 6 May 2019
Accepted 17 May 2019
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published 
by BMJ.
AbsTrACT
Gastric adenocarcinoma carries a poor prognosis, in part 
due to the late stage of diagnosis. Risk factors include 
Helicobacter pylori infection, family history of gastric 
cancer—in particular, hereditary diffuse gastric cancer 
and pernicious anaemia. The stages in the progression 
to cancer include chronic gastritis, gastric atrophy 
(GA), gastric intestinal metaplasia (GIM) and dysplasia. 
The key to early detection of cancer and improved 
survival is to non-invasively identify those at risk before 
endoscopy. However, although biomarkers may help in 
the detection of patients with chronic atrophic gastritis, 
there is insufficient evidence to support their use for 
population screening. High-quality endoscopy with full 
mucosal visualisation is an important part of improving 
early detection. Image-enhanced endoscopy combined 
with biopsy sampling for histopathology is the best 
approach to detect and accurately risk-stratify GA and 
GIM. Biopsies following the Sydney protocol from the 
antrum, incisura, lesser and greater curvature allow 
both diagnostic confirmation and risk stratification 
for progression to cancer. Ideally biopsies should be 
directed to areas of GA or GIM visualised by high-quality 
endoscopy. There is insufficient evidence to support 
screening in a low-risk population (undergoing routine 
diagnostic oesophagogastroduodenoscopy) such as the 
UK, but endoscopic surveillance every 3 years should be 
offered to patients with extensive GA or GIM. Endoscopic 
mucosal resection or endoscopic submucosal dissection 
of visible gastric dysplasia and early cancer has been 
shown to be efficacious with a high success rate and low 
rate of recurrence, providing that specific quality criteria 
are met.
ExECuTivE summAry
Gastric adenocarcinoma continues to be a frequent 
cause of death in the world and is the 16th most 
common cancer in the UK. The most common 
stages in the progression to gastric adenocarci-
noma are gastric atrophy (GA) and gastric intestinal 
metaplasia (GIM), which are collectively known as 
chronic atrophic gastritis (CAG). These conditions 
are principally caused by Helicobacter pylori infec-
tion and less commonly by autoimmune gastritis. 
The key to having a significant impact on the prog-
nosis of gastric adenocarcinoma and its economic 
burden is to accurately identify individuals at 
greatest risk and intervene with recognised effi-
cacious treatments, including endoscopic resec-
tion,before cancer is established. The British Society 
of Gastroenterology (BSG) endoscopy committee 
agreed to create a guideline to provide statements 
and recommendations on the prevalence, risks, 
diagnosis, treatment, surveillance and screening of 
gastric premalignant and early gastric malignant 
lesions. The principal patient group are those found 
to have GA, GIM, gastric epithelial dysplasia or 
early gastric adenocarcinoma limited to the mucosal 
or superficial submucosal layers. The target users 
include gastroenterologists, GI surgeons, pathol-
ogists, endoscopists and general practitioners. We 
followed the Appraisal of Guidelines for Research 
and Evaluation (AGREE II) instrument, and the 
quality of the evidence was assessed according to 
the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system.
A series of statements, recommendations and 
suggestions are proposed to ensure that there is 
consistency of practice, such that patients with 
gastric premalignant and early gastric malignant 
lesions are provided with optimal care. These 
recommendations are listed below:
1. We recommend H. pylori eradication to reduce 
the risk of gastric adenocarcinoma development 
in patients who have GA (evidence level: high 
quality; grade of recommendation: high; level 
of agreement: 100%).
2. We suggest that H. pylori eradication may be 
of some benefit to reduce the risk of developing 
gastric adenocarcinoma in those who already 
have H. pylori-associated GIM, dysplasia or 
cancer (evidence level: high quality; grade of 
recommendation: weak; level of agreement: 
100%).
3. We do not recommend the use of biomarkers as 
a screening tool in areas with a low incidence 
of gastric adenocarcinoma, such as the UK (ev-
idence level: low quality; grade of recommen-
dation: weak; level of agreement: 93%).
4. We recommend that patients at higher risk for 
gastric adenocarcinoma, including GA and 
GIM, should undergo a full systematic endos-
copy protocol of the stomach with clear pho-
tographic documentation of gastric regions and 
pathology. We suggest a minimum examination 
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time of 7 min (evidence level: moderate quality; grade of 
recommendation: strong; level of agreement: 100%).
5. GAand GIM may be detectable by white light endosco-
py (WLE); however, the accuracy is poor. Therefore, we do 
not recommend establishing a diagnosis or risk stratification 
using WLE alone (evidence level: moderate quality; grade of 
recommendation: strong; level of agreement: 93%).
6. We recommend image-enhanced endoscopy (IEE) as the best 
imaging modality to accurately detect and risk-stratify GA 
and GIM (evidence level: moderate quality; grade of recom-
mendation: strong; level of agreement: 100%).
7. We recommend that endoscopic appearances on WLE sugges-
tive of GA or GIM require escalation to high-resolution IEE 
and, where available, magnification endoscopy (evidence 
level: low quality; grade of recommendation: strong; level 
of agreement: 100%).
8. We recommend that the location and extent of GA and GIM 
should be clearly documented with photographic evidence. 
Endoscopic grading should be documented as distal gastric 
(affecting antrum or incisura—low risk) or proximal gastric 
(affecting the corpus with or without the antrum and incisu-
ra—high risk) (evidence level: low quality; grade of recom-
mendation: strong; level of agreement: 93%).
9. We recommend that endoscopic appearances on WLE of gas-
tric dysplasia and early gastric cancer (differences in colour, 
loss of vascularity, slight elevation or depression, nodularity, 
thickening, and abnormal convergence or flattening of folds) 
require escalation to IEE and, where available, magnifica-
tion endoscopy (evidence level: low quality; grade of recom-
mendation: strong; level of agreement: 100%).
10. We recommend IEE as the best imaging modality to accu-
rately diagnose and stage gastric dysplasia and early gastric 
cancer (evidence level: moderate quality; grade of recom-
mendation: strong; level of agreement: 100%).
11. We recommend that patients with image-enhanced features 
of CAG should undergo biopsies for confirmation of endo-
scopic diagnosis; biopsies are directed at mucosal sites 
within Sydney protocol areas where enhanced imaging 
discloses GIM. Biopsy samples should be collected in sepa-
rate containers and labelled as either ‘directed' or ‘random’ 
to corroborate endoscopic staging assessment (evidence 
level: low quality; grade of recommendation: strong; level 
of agreement: 93%).
12. We suggest that a baseline endoscopy with biopsies should 
be considered in individuals aged ≥50 years, with labora-
tory evidence of pernicious anaemia, defined by vitamin B12 
deficiency and either positive gastric parietal cell or intrinsic 
factor antibodies. As GA affects the corpus in pernicious 
anaemia, biopsies should be taken from the greater and lesser 
curves (evidence level: low quality; grade of recommenda-
tion: weak; level of agreement: 93%).
13. We recommend endoscopic surveillance every 3 years should 
be offered to patients diagnosed with extensive GA or GIM, 
defined as that affecting the antrum and body (evidence 
level: low quality; grade of recommendation: strong; level 
of agreement: 100%).
14. We do not recommend surveillance in patients with GA or 
GIM limited just to the gastric antrum unless there are addi-
tional risk factors, such as a strong family history of gastric 
cancer or persistent H. pylori infection, then we suggest 
3-yearly surveillance (evidence level: low quality; grade of 
recommendation: strong; level of agreement: 93%).
15. We recommend that patients with non-visible, low-grade 
dysplasia (LGD) should undergo a second endoscopy with 
enhanced imaging and extensive biopsy sampling, followed 
by a repeat endoscopy within 1 year if no visible neoplasia is 
detected. If there is persistent, non-visible LGD, endoscopy 
should be repeated annually thereafter (evidence level: low 
quality; grade of recommendation: strong; level of agree-
ment: 100%).
16. We recommend that patients with non-visible, high-grade 
dysplasia (HGD) should undergo an immediate second 
endoscopy with enhanced imaging and extensive biopsy 
sampling. We recommend ongoing surveillance at 6-monthly 
intervals for persistent, non-visible HGD. HGD should be 
discussed at the regional upper GI cancer multidisciplinary 
team and referred to a clinician with the appropriate exper-
tise (evidence level: low quality; grade of recommendation: 
strong; level of agreement: 100%).
17. We recommend that all gastric dysplasia and early gastric 
adenocarcinoma should be resected en bloc (an endoscopic 
mucosal resection (EMR) technique can achieve en bloc 
excision for lesions ≤10 mm in size, but only an endoscopic 
submucosal dissection (ESD) technique can ensure en bloc 
excision for lesions >10 mm in size) (evidence level: high 
quality; grade of recommendation: strong; level of agree-
ment: 100%).
18. We recommend that complete (R0) endoscopic resection of 
gastric dysplasia and early gastric adenocarcinoma with the 
following features should be considered as curative:
1. LGD.
2. HGD.
3. Well or moderately differentiated intramucosal adeno-
carcinoma, irrespective of size and without ulceration.
4. Well or moderately differentiated intramucosal adeno-
carcinoma, <3.0 cm in size if ulcerated.
5. Well or moderately differentiated submucosal adenocar-
cinoma, <3.0 cm in size, with superficial submucosal 
invasion (Sm1; <500 μm submucosal invasion as mea-
sured in a straight line from the deepest fibre of the mus-
cularis mucosae).
6. Poorly differentiated intramucosal adenocarcino-
ma, ≤2.0 cm in size (evidence level: moderate quality; 
grade of recommendation: strong; level of agreement: 
93%).
19. The histopathological features of early gastric adenocarci-
noma associated with a higher risk of lymph node metas-
tasis (LNM) after endoscopic resection include the following:
1. Poorly differentiated submucosal cancer, irrespective of 
invasion depth below muscularis mucosae.
2. Signet ring cancer.
3. Lymphovascular invasion.
4. Depth of submucosal invasion ≥500 μm as measured in 
a straight line from the deepest fibre of the muscularis 
mucosae (evidence level: moderate quality; grade of rec-
ommendation: strong; level of agreement: 93%).
20. We do not recommend the use of non-steroidal anti-in-
flammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) 
inhibitors to reduce the risk of progression of premalignant 
lesions of the stomach (evidence level: moderate; grade of 
recommendation: strong; level of agreement 100%).
21. We do not recommend the use of antioxidants as a means 
to reduce the prevalence of premalignant gastric lesions 
(evidence level: moderate; grade of recommendation: 
strong; level of agreement: 100%).
22. We suggest endoscopic screening should be considered in indi-
viduals aged ≥50 years with multiple risk factors for gastric 
adenocarcinoma (male, smokers, pernicious anaemia)—in 
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particular, in those with a first-degree relative with gastric 
cancer (evidence level: low quality; grade of recommenda-
tion: weak; level of agreement: 100%).
23. We do not recommend endoscopic screening for gastric 
adenocarcinoma in the UK population (evidence level: low 
quality; grade of recommendation: strong; level of agree-
ment: 100%).
24. We recommend that the number of gastric polyps (or esti-
mated number), location of polyps and size of the largest 
polyp should be clearly documented (evidence level: low 
quality; grade of recommendation: strong; level of agree-
ment: 100%).
25. We recommend that gastric polyps other than fundic gland 
polyps (FGPs) should be biopsied for histopathological 
assessment (evidence level: low quality; grade of recommen-
dation: strong; level of agreement: 100%).
26. We recommend that photographic documentation should 
be undertaken for all polyps or representative polyps, if 
numerous (evidence level: low quality; grade of recommen-
dation: strong; level of agreement: 100%).
27. We recommend that if adenomas or hyperplastic polyps are 
present, the background mucosa should be endoscopically 
assessed for GA, GIM, H. pylori and synchronous neoplasia 
(evidence level: moderate quality; grade of recommenda-
tion: strong; level of agreement: 100%).
28. We recommend that all adenomas should be resected when 
clinically appropriate and safe to do so (evidence level: low 
quality; grade of recommendation: strong; level of agree-
ment: 100%).
29. We recommend that a follow-up gastroscopy should be 
performed at 12 months after complete endoscopic exci-
sion of adenomas, then ongoing surveillance gastroscopy 
annually thereafter, when appropriate (evidence level: low 
quality; grade of recommendation: strong; level of agree-
ment: 93%).
30. We suggest that hyperplastic polyps >1 cm, pedunculated 
morphology and those causing symptoms (obstruction, 
bleeding) should be resected. If present, H. pylori should 
be eradicated before re-evaluation for endoscopic therapy 
(evidence level: low quality; grade of recommendation: 
weak; level of agreement: 100%).
31. We suggest that enhanced endoscopic imaging is used to aid 
characterisation of gastric polyps when there is diagnostic 
uncertainty following white light examination (evidence 
level: low quality; grade of recommendation: weak; level of 
agreement: 93%).
Three pathways have been created to allow a quick reference 
to the management of CAG, gastric dysplasia and gastric epithe-
lial polyps (Figure 1).
bACkGround
Gastric adenocarcinoma is a major cause of cancer mortality 
worldwide.1–3 In the UK in 2016, there were 5314 cases of 
gastric cancer, which has been declining gradually with the inci-
dence of H. pylori infection. Although there has been a decline in 
the incidence over the past 50 years, studies have demonstrated 
an increasing incidence of gastric adenocarcinoma among young 
white people in the USA, alongside a Swedish study demon-
strating an increasing incidence of premalignant gastric lesions 
among adults aged 35–44 years.4 5 These studies may suggest 
that historically declining gastric adenocarcinoma incidence 
rates may alter. At present within the UK, gastric cancer is the 
16th most common cancer, within Europe it is the sixth most 
common cancer, and worldwide it is the fifth most common.1–3 
Importantly, with the exception of Japan and South Korea, the 
majority of gastric cancers worldwide are diagnosed at a late 
stage, resulting in poor prognosis with a 29% average 5-year 
survival.3 6 The UK all-stage average 5-year survival rate is 18%, 
compared with an 80% average 5-year survival for stage 1A.3 
Clearly, Japan’s earlier stage of diagnosis and superior 5-year 
survival highlight the need for earlier recognition and treatment 
to overcome this bleak prognosis.7
The key to having a significant impact on the prognosis of 
gastric cancer and its global economic burden is to accurately 
identify the individuals who are at greatest risk and intervene, 
before gastric cancer development, through recognised effica-
cious treatments, including endoscopic resection. The canon-
ical model for cancer progression in the stomach is the Correa 
sequence, which outlines a stepwise linear progression from 
chronic gastritis through GA, GIM, dysplasia and finally, invasive 
cancer.8 This model was amended to involve the role of H. pylori 
as the prime causative environmental agent9 and has remained 
the dominant model since. Diagnosis and surveillance of higher 
risk patients in this cascade have been proposed as a strategy to 
reduce the mortality and morbidity of gastric adenocarcinoma.
The first international guidelines on the management of 
precancerous conditions and lesions in the stomach (MAPS) were 
published in 2012 by an international guidelines development 
group.10 These have not yet been revised. There is significant 
heterogeneity of practice in the management of premalignant 
and early malignant gastric lesions in the UK, partly because few 
endoscopists follow MAPS guidance.
objECTivEs
The objectives of these guidelines are to summarise the current 
evidence and to provide recommendations on the diagnosis, 
risks and management of gastric premalignant and early malig-
nant lesions, including GA, GIM, dysplasia and early adenocar-
cinoma. These guidelines are intended for the UK population.
mEThodoloGy
The guideline was commissioned by the BSG in May 2015 
and the proposal approved by Clinical Standards and Services 
Committee. The guideline was developed in line with the BSG 
guideline Process.11 The purpose of the guideline was to provide 
guidance to healthcare professionals who are involved in the 
care of patients at risk of gastric cancer, including gastroenterol-
ogists, GI surgeons, pathologists, endoscopists and general prac-
titioners. The AGREE II instrument (May 2009)12 was used to 
guide the methodology. The chair (MB) convened a guideline 
development group (GDG), consisting of clinicians and patients 
with experience of, or in the management of, these conditions. 
Members of the GDG were selected to ensure the relevant 
professional bodies and specialties were represented, including 
gastroenterologists, surgeons and pathologists. GDG members 
were required to declare any conflict of interests. The scope and 
purpose of the guidelines were initially discussed by the GDG 
on 20 July 2015 at the first consensus meeting, following which 
a set of key questions were created. The key questions were 
subdivided into clinical groups, including diagnosis, treatment, 
surveillance, screening and research (table 1). The GDG then 
voted anonymously on the relevance of each question to the 
guidelines and those with <75% agreement were excluded. The 
GDG then met in London on 17 September 2015 for a second 
consensus meeting to discuss the agreed key questions, agree on 
methodology, and allocate leads and subgroups to each question. 
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Figure 1 (A) British Society of Gastroenterology (BSG) guidelines for the endoscopic management of chronic atrophic gastritis. (B) BSG guidelines 
for the endoscopic management of gastric dysplasia. (C) BSG guidelines for the endoscopic management of gastric epithelial polyps. CAG, chronic 
atrophic gastritis; FAP, familial adenomatous polyposis; FGP, fundic gland polyp; GIM, gastric intestinal metaplasia. 
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Each lead and subgroup formulated a set of clinical questions 
pertinent to each key question using the PICO (patients, inter-
ventions, controls and outcomes) system, within which these 
four critical components were predefined as precisely as possible. 
The importance of each PICO outcome was ranked numerically 
by the subgroups on a 1–9 scale (7–9: critical; 4–6: important; 
1—3: of limited importance) according to the clinical impor-
tance of each. Those outcomes of ≤3 were excluded.
literature searches, evidence synthesis and grading of 
evidence
A literature search was undertaken by each subgroup with 
predefined search terms, electronic databases used (PubMed, 
Embase, Cochrane and Medline) and the time period covered. 
Where appropriate, conference abstracts were used to help 
formulate recommendations, provided that these were of suffi-
cient scientific rigour.
The PICOs were used to guide the search for evidence and the 
highest quality studies were prioritised. Systematic reviews or 
meta-analyses were selected initially. Where systematic reviews, 
meta-analyses or critically appraised articles were unavailable, 
lower levels of evidence were selected. Where reviews use poor-
quality studies such as that by Spence et al,13 for example, where 
the review was based on small, often single-centre cohort studies 
resulting in high levels of heterogenicity, this is discussed in 
the evidence review and highlighted in the evidence tables. In 
this instance, more weight is given to larger studies using large 
databases, which are likely to be more accurate. This hierarchy 
of searching was performed in a pyramidal sequence from top 
(high quality) to bottom (low quality), cascading from recently 
published systematic reviews of randomised controlled trials 
(RCTs) or observational studies, to RCTs, and subsequently to 
observational studies providing that no evidence is available 
from the higher quality categories. The selected evidence was 
Table 1 Key questions, subgroups and leads
Question lead subgroup
Diagnosis: overview
  What are the epithelial glandular precancerous lesions of the stomach, what is their 
prevalence within the UK and what risks do they present?
Dr David Graham Matthew Banks, Ernst Kuipers, Mario Dinis-Ribeiro, Marnix 
Jansen, Marco Novelli, Manuel Rodriguez-Justo, Neil Shepherd
  Are there groups of individuals (without known precancerous lesions) known to be 
at increased risk of glandular gastric cancer—for example, family history, ethnic 
origin, genotype and phenotype?
Dr Massimiliano Di 
Pietro
Matthew Banks, Sergio Coda, David Graham, Noriya Uedo
  Who should be screened for Helicobacter pylori to reduce gastric cancer and how 
should they be screened? Does eradication prevent progression to glandular gastric 
cancer?
Professor Mark 
Pritchard
Matthew Banks, Takuji Gotoda, Ernst Kuipers, David Graham
  What blood tests are useful in the management of precancerous gastric lesions? 
Can they be applied for population screening, monitoring those at risk or those with 
known lesions?
Dr David Graham Matthew Banks, Mario Dinis-Ribeiro, Mark Pritchard
Diagnosis: endoscopy
  Outside the recommendations within the UK guidelines for the quality of 
endoscopy, are there further processes that are suggested for the detection and 
diagnosis of premalignant or early malignant lesions of the stomach?
Professor Takuji Gotoda Matthew Banks, Krish Ragunath, David Graham, Sergio Coda
  How does one identify premalignant or early malignant lesions and ensure accurate 
documentation when reporting? Is a station-based approach beneficial and are 
there mucosal features that identify these lesions (including recognising the 
atrophic border)?
Mr Sergio Coda Matthew Banks, Takuji Gotoda, Noriya Uedo, Pradeep Bhandari, 
Krish Ragunath, David Graham
  What biopsy strategy should be adopted for the sampling and reporting of the 
premalignant or early malignant stomach? Should all those undergoing routine 
endoscopy be biopsied or are there groups to target?
Dr Marnix Jansen Matthew Banks, David Graham, Sergio Coda, Marco Novelli, 
Manuel Rodriguez-Justo, Neil Shepherd
  What histopathogical and imaging modalities are suggested for the staging of 
glandular premalignant and early gastric malignant lesions of the stomach?
Mr Sergio Coda Marnix Jansen, Matthew Banks, David Graham, Sergio Coda, 
Marco Novelli, Manuel Rodriguez-Justo, Neil Shepherd
Surveillance
  Should individuals with premalignant gastric glandular lesions undergo 
surveillance? If so, what are the recommendations?
Dr Matthew Banks Mario Dinis-Ribeiro, David Graham, Massimiliano di Pietro, Ernst 
Kuipers
Treatment: endoscopy
  What lesions are amenable for endoscopic removal? How should these lesions 
be removed? Are there criteria for histopathological assessment that determine 
prognosis and follow-up?
Professor Pradeep 
Bhandari
Matthew Banks, Krish Ragunath, Takuji Gotoda, Noriya Uedo, 
David Graham
Treatment: pharmacological
  Is there a role for other pharmacological treatments—for example, cyclo-
oxygenase-2 inhibitors and antioxidants?
Dr David Graham Matthew Banks
Screening
  Is there evidence to support the introduction of a population screening programme 
for glandular gastric cancer?
Dr Matthew Banks Mark Pritchard, David Graham
Gastric polyps 
What are the epithelial gastric polyps and how should they be managed? Dr Matthew Banks Sergio Coda, Mark Pritchard, Pradeep Bhandari
Research
  Are there recommendations for future research into the diagnosis and management 
of premalignant and early malignant lesions of the stomach?
Dr Matthew Banks Marnix Jansen, David Graham
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tabulated in an evidence table categorising each study into the 
study design, intervention/clinical question, participants/popula-
tion, reference standard, results and conclusions/comments.
Although randomised controlled studies are deemed the most 
appropriate type of study to assess the effectiveness of an inter-
vention, other types of studies were included to assess types of 
effectiveness, such as ways of delivering service or outcomes from 
registries in clinical practice. If evidence from studies was weak 
or contradictory, searches for alternative sources were under-
taken to see if the evidence concurred or contradicted (triangu-
lation of searches). All available negative studies were included 
in the searches. The subgroups discussed the external validity 
of the studies and whether the study outcomes are applicable to 
the target population for the guidelines. Literature searches were 
transparent and reproducible to reduce ‘dissemination biases’.
All evidence tables and references were downloaded to a 
shared reference manager (F1000Workspace), to which all GDG 
members had access. Shortly before the statements were final-
ised, a further literature search was undertaken. The quality of 
the evidence was assessed following the GRADE terminology 
using table 2.14 Evidence is graded as high, moderate, low and 
very low quality (table 2).
recommendations
The body of evidence for many questions was of low quality. 
Thus many statements were based on the consensus of the GDG 
given the limitations of the evidence.
Recommendations were made by each subgroup pertaining to 
the PICOs and graded as above with the strength of each recom-
mendation. Recommendation strength is based on four factors:
1. Balance between desirable and undesirable effects (not con-
sidering cost).
2. Quality of the evidence across critical/important outcomes.
3. Patients’ values and preferences.
4. Costs (resource use).
There are two grades of recommendations: strong, where 
the benefits clearly outweigh the risks and burden (‘We recom-
mend’); and weak, where the benefits were closely balanced with 
risks/burden (‘We suggest’).
Once consensus was reached within the subgroup, the level 
of agreement for the recommendations was obtained from the 
whole GDG by anonymised voting. Level of agreement was 
subdivided into five categories: strongly agree, agree, undecided, 
disagree and strongly disagree. All comments were used to amend 
recommendations where appropriate, and a second round of 
voting was undertaken for any modifications. All results and 
comments were anonymously sent to the GDG Chairman (MB). 
Where the GDG level of agreement was consistently below 90% 
for strongly agree and agree after three rounds of voting, the 
recommendation was excluded.
summAry oF sTATEmEnTs, rECommEndATions And 
suGGEsTions
Pathogenesis, diagnosis and epidemiology of premalignant 
and early malignant gastric lesions
Pathogenesis and epidemiology of premalignant and early 
malignant gastric lesions
What are the precancerous lesions of the stomach, what is their 
prevalence within the UK and what risk do they confer?
Patients with GA and GIM have an increased risk of gastric 
adenocarcinoma. Increased severity of atrophy and extent of 
intestinal metaplasia is associated with an increased risk of cancer 
(evidence level: moderate quality; level of agreement: 100%).
Visible low-grade gastric dysplasia has an increased risk of 
prevalent HGD and gastric adenocarcinoma (evidence level: low 
quality; level of agreement: 100%).
Non-visible, low-grade gastric dysplasia increases the risk 
of gastric adenocarcinoma, but the magnitude of this risk is 
unknown (evidence level: low quality; level of agreement: 93%).
Gastric HGD carries a significant risk of progression to gastric 
adenocarcinoma (evidence level: moderate quality; level of 
agreement: 100%).
GA, Gim and dysplasia
For the purposes of this guideline, CAG collectively includes 
GA and GIM. It is important to define the histopathology of 
the premalignant stomach in order to understand progression 
to cancer and its endoscopic appearances. The normal gastric 
mucosa is divided into two compartments, and includes the 
gastrin and mucus-secreting glands of the antrum and the acid 
and pepsinogen-secreting oxyntic glands of the corpus. GA is 
defined as the loss of pre-existent glands native to the gastric 
compartment. The two phenotypic features of GA include the 
loss of glandular mass with fibrosis of the lamina propria and 
Table 2 Evidence level
Evidence level
High quality One or more well-designed and well-executed randomised controlled trials (RCTs) that yield consistent and directly applicable results
This level also means that further research is very unlikely to change our confidence in the estimate of effect
Moderate quality RCTs with important limitations (ie, biased assessment of the treatment effect, large loss to follow-up, lack of blinding, unexplained heterogeneity), indirect 
evidence originating from similar (but not identical) populations of interest and RCTs with very small numbers of participants or observed events
In addition, evidence from well-designed controlled trials without randomisation, from well-designed cohort or case-controlled analytical studies, and from 
multiple time series with or without intervention is included in this category
This level also means that further research will probably have an important impact on our confidence in the estimate of effect and may change the 
estimate
Low quality Observational studies would typically be rated as low quality because of the risk for bias*
This level also means that further research is very likely to have an important impact on our confidence in the estimate of effect and will probably change 
the estimate
Very low quality† Evidence is conflicting, of poor quality or lacking, and hence the balance of benefits and harms cannot be determined
Any estimate of effect is very uncertain as evidence is either unavailable or does not permit a conclusion
*Quality of evidence based on observational studies may be rated as moderate or even high, depending on circumstances under which evidence is obtained from observational 
studies. Factors that may contribute to upgrading the quality of evidence include a large magnitude of the observed effect, a dose–response association or the presence of 
an observed effect when all plausible confounders would decrease the observed effect.
†Insufficient evidence to determine for or against routinely providing a service.
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replacement of the native gastric glands by metaplastic or pseu-
dopyloric glands.
The Correa cascade describes the stepwise progression of 
precursor lesions towards intestinal-type gastric cancer.9 H. 
pylori infection initiates the cascade through non-atrophic 
chronic gastritis, GA, GIM and finally, dysplasia.15
Gastric atrophy
GA is diagnosed histopathologically by two specific features: the 
presence of chronic inflammatory cells, including lymphocytes 
and plasma cells that expand the lamina propria, and the loss of 
the pre-existent gastric glands.
There is inconsistency in the histopathological diagnosis and 
severity of GA between pathologists, resulting in low interob-
server agreement by histopathologists when staging GA using 
the OLGA (Operative Link on Gastritis Assessment) staging 
system, based on biopsies taken using the Sydney protocol.16 17 
Recent studies, however, have demonstrated that accurate endo-
scopic staging of the severity of GA are strongly linked to gastric 
adenocarcinoma risk and that the interobserver and intraob-
server agreement of endoscopic severity assessment, in experi-
enced hands, is moderate to excellent.16 18
The prevalence of CAG (including GA) worldwide correlates 
with the prevalence of H. pylori-associated gastritis, increases 
with age and tends to be slightly more common in men. Prev-
alence is typically determined using gastroscopy and serum 
pepsinogen. In Western populations, the prevalence varies from 
0% to 8.3%, depending on age.4 19–21 Studies performed in 
high-incidence areas such as Japan and China showed a preva-
lence of CAG of between 33% and 84%.20 22 23
Studies exploring the risk of progressing from CAG to gastric 
adenocarcinoma report a range of between 0% and 10%, with 
an annual incidence (person-year) of <1% (range 0–1.2%). This 
is regardless of whether the study population is from a high-
risk or low-risk area.13 24 This is roughly comparable with other 
premalignant conditions of the digestive tract, such as Barrett’s 
oesophagus and colonic adenomatous polyps, where there are 
established guidelines on surveillance. A Swedish observational, 
population-based cohort study, reviewing biopsy samples of 
405 172 patients from 1979 to 2011, demonstrated that 1 in 
50 patients with GA would develop gastric adenocarcinoma 
within 20 years (an annual risk of progression of 0.1%).15 A 
second Dutch study exploring the follow-up data on 22 365 
patients diagnosed with CAG found the overall annual incidence 
for the development of gastric cancer in patients with GA was 
0.1%.25 This increased to 0.25% for GIM, 0.6% for LGD and 
6% for HGD within 5 years after diagnosis. A recent systematic 
review found that the annual incidence in most studies varied 
from 0.1% to 0.5%, but a pooled analysis was not undertaken as 
there was significant heterogeneity between studies (I2 statistic of 
94%).13 This is partly explained by the poor quality of evidence 
in this systematic review derived from small cohorts of patients 
from single centres.
Using endoscopic grading, Japanese investigators found the 
cumulative 5-year incidence of gastric adenocarcinoma to be 
0.7% in those with no or mild GA on endoscopic assessment, 
1.9% with GA and 10% in severe endoscopic GA.26
Gastric intestinal metaplasia
GIM is a common finding in studies of patients undergoing 
diagnostic upper GI endoscopy—in particular, in those with 
a current or past H. pylori infection. GIM prevalence also 
increases with H. pylori infection, patient age, smokers and also 
with a first-degree relative with gastric cancer. The overall prev-
alence of GIM in those undergoing routine endoscopy varies 
from 13.8% to 19% in Europe.27 28 It is important to point out 
that the European population is not uniformly representative of 
that in the UK. For example the population studied by Olmez 
et al is from a high prevalence area of Eastern Turkey. A Dutch 
study found GIM to be present in 25.3% of patients undergoing 
endoscopy for dyspepsia.29 The prevalence in those infected 
with H. pylori was 33.9% compared with 15.2% of those who 
were not infected. This study also noted that GIM was present 
in 55% of patients with gastric ulcer and 100% of patients with 
intestinal-type gastric adenocarcinoma. A multicentre European 
study found the prevalence of GIM to be 31.4% in patients 
infected with H. pylori.30 In high-incidence areas such as Japan 
and China, the prevalence of GIM in H. pylori-infected individ-
uals was 37% and 29.3%, respectively.31 GIM was found in only 
2% of those not infected with H. pylori.15 32
The risk of gastric adenocarcinoma is increased in those found 
to have GIM. One in 39 patients with GIM develops gastric 
adenocarcinoma within 20 years,15 with similar rates found by 
De Vries et al with an annual incidence of cancer of 0.25% at 
5 years.25 A meta-analysis carried out by Zullo et al in 2000 found 
that the risk of gastric adenocarcinoma progression in those with 
GIM ranged from 0% to 10%, with this range thought to be due 
to differing study sample sizes and follow-up periods.32 Simi-
larly, a systematic review by Spence et al found the annual inci-
dence in most studies ranged from 0.15% to 0.4%.13
The risk of gastric adenocarcinoma varies with the type and 
extent of GIM. There are three histological types of GIM, with 
type I or ‘intestinal’ being termed ‘complete IM’ and types II 
and III or ‘colonic’ termed ‘incomplete IM’. ‘Incomplete IM’ 
has been suggested to carry an increased cancer risk compared 
with ‘complete IM’.32–34 A Portuguese study showed that 31% 
and 6.9% of those with ‘incomplete IM’ developed LGD and 
HGD, respectively, compared with only 8% of those with 
‘complete IM’, who developed LGD only.35 Therefore, histolog-
ical subtyping may have a role in establishing gastric cancer risk, 
although it should be noted that only a minority of patients with 
invasive gastric cancer seem to have incomplete IM. Addition-
ally, it should be noted that the traditional diagnosis of ‘complete 
IM’ or ‘incomplete IM’ is made using enzyme-histochemical 
staining methods that are highly dependent on the person eval-
uating them and thus are not reproducible. Therefore, the GDG 
did not consider histological subtyping for the guidelines.
The extent of the distribution of GIM appears to be of 
key importance. Four patterns of GIM distribution have 
been described.36 The first, ‘focal’ GIM, consists of scattered 
foci, mostly in the lesser curvature and incisura. The second, 
‘antrum-predominant’ GIM, involves most of the antrum 
and incisura angularis. These two patterns with less extensive 
involvement of the gastric mucosa consist almost exclusively 
of complete type IM. The third, ‘magenstrasse’ GIM spreads 
throughout the lesser curvature from the cardia to the pylorus, 
also involving the greater curvature of the prepyloric antrum. 
The fourth, ‘diffuse’ GIM involves the entire gastric mucosa, 
with the exception of the fundic areas. These more extensive 
types had a greater predominance of ‘incomplete’ GIM.
Several studies have demonstrated that more extensive GIM 
correlates with increased gastric adenocarcinoma risk.32 36–38 Of 
note, a Columbian study found that in comparison with focal or 
antral-predominant GIM, those with magenstrasse GIM had a 
5.7-fold increased risk of gastric adenocarcinoma, while those 
with a diffuse pattern (antrum and gastric body) had a 12.2-
fold increased risk. Alongside this, an Italian study showed that 
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a >20% extension of GIM identified those at increased risk.32 A 
Japanese study found the cumulative 5-year incidence of gastric 
adenocarcinoma to be 1.5% in those without GIM, compared 
with 5.3% in those with GIM in the antrum only and 9.8% in 
those with GIM in the antrum and corpus.26
Unlike the OLGA staging system, the OLGIM (Operative Link 
on Gastric Intestinal Metaplasia) staging system, using the pres-
ence of GIM, has proved to be a reproducible marker of risk 
with high interobserver agreement and strong association with 
OLGA stage.39 40 The GDG did not agree that OLGIM should 
be routinely used in clinical practice, although it has practical 
applicability in research.
Intestinal metaplasia of the gastric cardia has been reported to 
vary from 5% to 25% in those having endoscopy41 42 and may 
confer an increased risk of dysplasia and cancer, although the inci-
dence is not clear. Sharma and colleagues found 1 of 76 patients 
with prevalent LGD in cardia intestinal metaplasia, defined as 
that just below the gastro-oesophageal junction, compared with 
20 of 177 having low-grade and high-grade dysplasia with short 
segment Barrett’s oesophagus (<3 cm).43
Gastric dysplasia
The endoscopic prevalence of gastric dysplasia varies from 0.5% 
to 3.7% in Western countries and from 9% to 20% in areas with 
a high incidence of gastric adenocarcinoma.44–47 The identifica-
tion of gastric dysplasia should also alert the endoscopist to the 
possibility of synchronous gastric cancer. Studies have demon-
strated the incidence of synchronous gastric adenocarcinoma in 
those with gastric dysplasia to be up to up to 30%.44
A review of the natural history of gastric dysplasia showed that 
patients with HGD had a rate of malignant progression or 
synchronous malignant lesions of 60–85% over a median interval 
period of 4–48 months.44 Song et al, in their observational study, 
found that 1 in 19 patients with dysplasia progressed to gastric 
adenocarcinoma within 20 years, although no differentiation was 
made between those with LGD or HGD.15 de Vries et al noted 
the annual incidence of gastric cancer was 6% in patients with 
HGD within 5 years.25 Of note, it is difficult on histopathology 
to distinguish between HGD and gastric adenocarcinoma from 
small biopsy samples.
The risk of progression in individuals with LGD is less clear. 
There is evidence to show that LGD will regress in 38–75% of 
patients and persist in 19–50%. In the LGD lesions that persist, 
the risk of malignant progression ranges from 0% to 23% in the 
published literature over 10–48 months.44 de Vries et al reported 
that the annual incidence of gastric adenocarcinoma in those 
with LGD was 0.6% within 5 years after diagnosis.25
Visible LGD following resection is upstaged in 25–35% of 
lesions, including those of <1 cm, with an adenocarcinoma 
rate of 6.9%.44 We have therefore suggested that the risk of 
prevalent HGD or gastric adenocarcinoma is greater in visible 
LGD. Although there is uncertainty about the natural history of 
non-visible LGD, the evidence suggests that there is an increased 
rate of progression, but the magnitude is unclear.
A summary of the risks of gastric cancer is shown in table 3.
Risk factors for gastric adenocarcinoma
Are there groups of individuals (without known precancerous 
lesions) known to be at increased risk of gastric adenocarcinoma?
There are subgroups of individuals (other than those with H. 
pylori infection) who have an increased risk of gastric adenocarci-
noma. The strongest risk factors include family history of gastric 
adenocarcinoma and serologically confirmed pernicious anaemia 
with GA. Additional risk factors include non-white origin, history 
of gastric surgery for benign disease longer than 15 years, age older 
than 45 years, male sex, high salt intake and smoking (evidence 
level: low quality; level of agreement: 93%).
Several factors increase the risk of developing malignant 
lesions of the stomach, which should be taken into account 
when considering screening on an individual basis. These risk 
factors might help in the development of larger scale screening 
programmes in the future and relate to multiple subcategories 
including patient demographics and epidemiological factors, as 
well as personal, medical, social and family history. Unfortu-
nately, the grade of evidence on the link between risk factors and 
gastric cancer development is low, as this comes almost univer-
sally from retrospective or observational studies, including 
meta-analyses from these studies. The working group has anal-
ysed the evidence related to 11 risk factors based on the available 
literature.
Family history appears to be one of the strongest risk factors. 
Three case–control studies (from Japan, Poland and South Korea) 
for a total of 1024 gastric cancer cases showed that the OR for 
gastric adenocarcinoma in first-degree relatives of patients with 
gastric adenocarcinoma ranged from 2.3 to 3.5.47–50 In another 
US population case–control study, the risk of gastric adenocar-
cinoma was higher in subjects reporting two or more family 
members with gastric adenocarcinoma (OR=5–12.1, 95% CI 
1.35 to 108.5). Two additional studies have suggested that the 
risk is higher and the age of onset lower in those with a family 
history of early-onset (<50 years) gastric adenocarcinoma.51 52 
In addition, a retrospective cohort study on US veterans with 
GIM indicated that a family history of gastric adenocarcinoma 
was associated with a HR of 3.8 (95% CI 1.5 to 9.7) for gastric 
adenocarcinoma development.53 In keeping with this evidence, 
monozygotic and dizygotic twins of individuals with gastric 
adenocarcinoma have 9.9-fold and 6.6-fold higher risk of gastric 
adenocarcinoma, respectively, compared with twins of subjects 
without gastric adenocarcinoma.54 It is important to consider 
that familial aggregation occurs in approximately 10% of cases, 
which in low-incidence countries of gastric adenocarcinoma 
probably relates to heritable pathogenic mutations. However, 
truly hereditary cases are deemed to account for approximately 
1–3% of all gastric adenocarcinoma cases and include three main 
subgroups: hereditary diffuse gastric cancer (HDGC), familial 
intestinal gastric cancer and other single-gene syndromes associ-
ated with a possible increased risk of gastric adenocarcinoma.55 
These single-gene syndromes include gastric adenocarcinoma and 
proximal polyposis of the stomach,56 57 Li-Fraumeni syndrome, 
Table 3 The risk of cancer for patients with gastric atrophy and 
intestinal metaplasia
5-year incidence of 
gastric cancer (%) Annual incidence (%)
All GA 1.9 0.1–0.5
Mild GA 0.7
Severe GA 10
All GIM 0.15–0.4
0.25
Antral GIM 5.3
Antral and corpus GIM 9.8
Interval of 4–48 months
Low-grade dysplasia 0–23 0.6
High-grade dysplasia 60–85 6
GA, gastric atrophy; GIM, gastric intestinal metaplasia.  
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familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome, 
juvenile polyposis, Cowden’s syndrome/PTEN hamartoma 
tumour syndrome (PTHS) and Lynch syndrome.58 More than 
90% of individuals with a phosphatase and tensin homolog 
(PTEN) pathogenic variant who underwent at least one upper or 
lower endoscopy were found to have polyps.59 Histological find-
ings varied, ranging from ganglioneuromatous polyps, hamarto-
matous polyps and juvenile polyps, to adenomatous polyps. The 
association of gastric cancer with FAP is mainly based on case 
reports and thus remains weak.
Although this guideline does not cover management of hered-
itary gastric cancer, it is important to know how to take an 
appropriate family history, in order to suspect familial gastric 
cancer and know when to refer for genetic counselling. Outside 
the specialised genetic counselling clinic, where the three-gen-
eration comprehensive pedigree is recommended, in standard 
clinical practice it is recognised that it is sufficient to focus on 
first-degree (parents, children and siblings) and second-degree 
relatives (grandparents, aunts/uncles, nieces/nephews, grand-
children and half siblings) in order to assess the empirical indi-
vidual risk profile.60 Affected relatives should be from the same 
lineage (maternal or paternal) and be first-degree relatives of 
each other. The age of diagnosis, the histological type of gastric 
cancer (if possible) and the occurrence of GI polyps and other 
cancers, including colorectal, ovarian, breast and pancreatic 
cancer, should be recorded. Criteria for referring to genetic 
services are outlined in box 1.61 62 It is important to note that 
the criteria for a clinical diagnosis of HDGC have been slightly 
relaxed in the more recent updated clinical guidelines. A history 
of breast cancer is particularly important for a clinical suspicion 
of familial gastric cancer as there is clustering between gastric 
and breast cancers in HDGC (lobular type) and in other familial 
cancer syndromes, including Peutz-Jeghers and Cowden.61 63 
Individuals who fulfil the family history criteria for suspected 
familial gastric cancer in the absence of an identified mutation 
could be considered for endoscopic surveillance. Ideally, this 
should be offered as part of a clinical trial as there are no vali-
dated surveillance protocols in this group of individuals. In the 
absence of evidence, we would suggest 3-yearly endoscopy with 
high-definition endoscopy and image enhancement as a possible 
protocol. Details of genetic centres in the UK can be found on 
the British Society for Genetic Medicine website (https://www. 
bsgm. org. uk).
Many genetic polymorphisms have been shown to be associ-
ated with an increased risk of gastric cancer, in particular related 
to inflammatory response genes, such as interleukins, interleukin 
receptors and tumour necrosis factor.64 There is insufficient 
evidence to recommend routine DNA genotyping to inform 
clinical decisions outside cases that meet the criteria for familial 
gastric cancer.55 A detailed discussion of this topic is beyond the 
scope of this guideline.
Pernicious anaemia is another strong risk factor for gastric 
adenocarcinoma development. A systematic review by Vannella 
and coworkers found that the pooled incidence of gastric adeno-
carcinoma in patients with pernicious anaemia is 0.27% a year 
with a relative risk (RR) of 6.8 (95% CI 2.6 to 18.1).65 A more 
recent population-based case–control study on 1 138 390 cancer 
cases compared with 100 000 matched controls found that in 
patients with pernicious anaemia, the ORs for gastric adenocar-
cinoma and gastric neuroendocrine tumours were 2.18 (95% CI 
1.94 to 2.45) and 11.4 (95% CI 8.9 to 14.7), respectively.66 
Since these were unverified cases of pernicious anaemia, this was 
probably a marked underestimate of the cancer risk in patients 
with definite pernicious anaemia. Substantiating a diagnosis of 
pernicious anaemia, however, can be challenging. Megaloblastic 
anaemia and vitamin B12 deficiency can depend on a multitude of 
clinical conditions, and the diagnostic accuracy of autoantibodies 
is low (low specificity for antiparietal cell antibodies and low 
sensitivity for anti-intrinsic factor antibodies).67 68 Therefore, in 
order to stratify cancer risk, it is essential that histopathological 
evidence of autoimmune atrophic gastritis corroborates the sero-
logical diagnosis.
It has long been suggested that a history of gastric surgery for 
benign disease is a risk factor for gastric adenocarcinoma. Three 
early retrospective cohort studies have shown an increased gastric 
adenocarcinoma risk in individuals carrying a gastric stump from 
previous surgery for non-malignant disease compared with the 
general population,69–71 while one case–control study did not 
reach similar conclusions.72 The discrepancy may be resolved by 
a more recent and large retrospective study, which found that the 
risk of gastric adenocarcinoma in a gastric stump only increases 
after 30 years from gastric surgery with a standardised incidence 
ratio of 2.29 (95% CI 1.38 to 3.57).73 Hence, it is reasonable 
to conclude that the risk of gastric adenocarcinoma arising in 
the gastric stump is unlikely to be significantly increased within 
the first 15 years after surgery. However, it should be noted that 
these data may be confounded by H. pylori status.
Ethnicity is strongly related to the risk of gastric adeno-
carcinoma. Several retrospective cohort studies conducted 
in US and UK populations showed that white subjects appear 
to have a lower risk than Asian subjects (2.1-fold higher inci-
dence), black subjects (1.7-fold higher incidence) and Hispan-
ic-Latino subjects (1.7-fold higher incidence).74–78 Among 
Asian people, Chinese and Korean subjects appear to have the 
highest risk of a premalignant stomach with an OR of 4.77 (95% 
CI 4.54 to 5.01) and 7.39 (95% CI 7.06 to 7.73), respectively.21 
These differences are likely to be, at least in part, explained by 
differences in H. pylori prevalence, H. pylori subtypes and host 
genotypes.
There is evidence that older age is a risk factor for developing 
gastric adenocarcinoma, reflecting the duration of H. pylori 
gastritis. Different studies report different age groups to study 
this association—for example, 45, 50 or 75 years of age; hence, 
it is difficult to identify an age cut-off point to guide clinical 
box 1 Criteria for referring to genetic services
suspected familial gastric cancer
 ► Gastric cancer in one family member before age 40.
 ► Or gastric cancer in two first-degree/second-degree relatives 
with one diagnosis before age 50*.
 ► Or gastric cancer in three first-degree/second-degree relatives 
independent of age*. 
suspected hereditary diffuse gastric cancer
 ► One case of diffuse gastric cancer before age 40.
 ► Or two cases of gastric cancer regardless of age in two 
first-degree/second-degree relatives, at least one confirmed 
diffuse gastric cancer*.
 ► Or personal and family history of diffuse gastric and lobular 
breast cancers, with one diagnosis before age 50.
 ► A personal or family history of cleft lip/palate in a patient 
with diffuse gastric cancer.
 ► In situ signet ring cells or pagetoid spread on gastric biopsies.
*In order to account for significant family history, the affected relatives 
need to be within the same side of the family (maternal or paternal).
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decisions.25 79 80 However, three studies have shown that age 
>45 years is associated with a significant OR between 1.92 and 
3.1 for progression of premalignant stomach to gastric adeno-
carcinoma.25 81 82 Hence, it is reasonable to consider 45 years of 
age as a useful threshold for potential screening strategies.
Men appear to be at increased risk of gastric adenocarci-
noma compared with women. Two cohort studies and one case–
control study showed different strengths of this association, with 
a relative incidence in men compared with women, ranging from 
1.3-fold to 3-fold higher.74 79 This does not apply to cases of 
gastric adenocarcinoma occurring before the age of 40 years, 
which are probably due to the domineering genetic background 
responsible for early-onset cancer.55 83
Smoking seems to be an additional risk factor for develop-
ment of gastric adenocarcinoma, particularly, but not limited to, 
gastric cardia adenocarcinoma. Smoking appears to be respon-
sible for 18% of gastric adenocarcinoma risk,84 and this relates 
to an increase in the risk by 1.45-fold to 2-fold according to 
different studies.85 86 However, one meta-analysis showed a 
trend for increased risk of gastric adenocarcinoma development 
only in current smokers, which did not meet statistical signifi-
cance (OR=1.49; 95% CI 0.99 to 2.225).87
Other risk factors that have been studied and were assessed 
by the working group include alcohol consumption, diabetes, 
obesity and use of protein pump inhibitors.88–90 For these factors 
the available evidence is conflicting or does not show a clear 
relation to the risk of gastric adenocarcinoma development. In 
particular for obesity there is sufficient evidence to conclude that 
this is associated with the risk of cardia cancer, but not non-cardia 
gastric cancer.91 A number of recent studies have investigated the 
association between PPIs and gastric cancer. A study by Cheung 
et al assessing patients who were treated for H. pylori demon-
strated an association between PPI use and gastric cancer in a 
population from Hong Kong. PPI use was associated with a 
2.44-fold increase in cancer. No increase was detected in H2 
antagonists, and most cancers were non-cardia. There were 
significant flaws in this study. Most importantly, the PPI group 
were 10 years older on average than the non-PPI group, and as 
gastric cancer increases with age it would be expected that the 
risk would be greater in this group. A Swedish study showed a 
similar increase in gastric cancer in PPI users, with the greatest 
risk in younger men. No difference was found, however, in a US 
study looking at pantoprazole. It can be concluded that although 
there is an association between PPI use and gastric cancer, no 
causal link has been proved. Furthermore, this association may 
be limited to specific populations and limited to patients who 
have had H. pylori eradication.92–94 We make reference to a BSG 
position statement,95 which recommends that if acid suppression 
is required after H. pylori eradication, H2 antagonists should be 
used first, and if these are ineffective PPIs can be initiated with 
the above information being shared with the patient. In other 
patients there is no evidence to advise against the use of PPIs first 
line for short-term use. Prolonged use should be accompanied 
by an explanation of the evidence for possible risks as described 
above.
H. pylori and gastric cancer
Who should be tested and treated for H. pylori to reduce the risk 
of gastric cancer?
We do not recommend testing and treating for H. pylori to 
reduce the incidence of gastric cancer in low-incidence areas such 
as the UK (evidence level: high quality; grade of recommenda-
tion: high; level of agreement: 100%).
Several studies in rodents support the hypothesis that eradi-
cation of H. pylori infection prevents the subsequent develop-
ment of gastric adenocarcinoma.96 97 However, the benefits were 
reduced in these animal models when infection was eradicated at 
later stages in the natural history of the disease. Multiple human 
cohort studies and randomised clinical trials have now been 
performed to assess whether testing for H. pylori in the asymp-
tomatic population and its subsequent eradication in infected 
subjects reduces the subsequent incidence of gastric cancer. In 
turn, these studies have been subjected to systematic reviews and 
meta-analyses by at least three independent research groups. 
It was concluded that searching for and eradicating H. pylori 
reduced the incidence of gastric adenocarcinoma in healthy 
asymptomatic infected individuals, with the number of patients 
needed to treat as low as 15 for Chinese men, but as high as 
245 for US women.98–100 The benefits of eradication varied with 
baseline gastric cancer incidence, but did not differ with study 
design, sex or follow-up period baseline risk.101
Thus, there is compelling evidence that H. pylori eradication 
is effective at reducing the subsequent risk of gastric adeno-
carcinoma development. In areas of low to moderate gastric 
adenocarcinoma incidence such as the UK, however, it has been 
suggested that this is not a cost-effective strategy. However, as 
recently argued by O’Connor et al,102 there may be additional 
benefits associated with H. pylori eradication, such as a reduction 
in peptic ulcer disease and dyspepsia, and these have not been 
considered in all the proposed economic models. Other poten-
tial consequences of widespread H. pylori eradication therapy 
should also be considered when considering the risk:benefit 
ratio of such a strategy. These include the potential emergence of 
antibiotic-resistant strains of the organism and treatment-associ-
ated side effects, some of which, although rare, can be serious, 
such as Clostridium difficile infection.102
Therefore, although H. pylori eradication is a feasible, effi-
cacious and potentially cost-effective method (at least in some 
populations) for reducing the risk of subsequent gastric adeno-
carcinoma development, its use has not yet been adopted 
anywhere in the world. The final results of a very large Chinese 
trial involving more than 180 000 participants will be available 
within the next few years, and its results may influence future 
public health policy in this area, particularly in East Asian coun-
tries.103 However, at present, in areas of relatively low gastric 
cancer incidence such as the UK, we cannot currently recom-
mend population testing and treating for H. pylori as a means for 
preventing subsequent gastric cancer development
Does eradication of H. pylori prevent progression to cancer?
We recommend H. pylori eradication to reduce the risk of 
gastric adenocarcinoma development in patients who have 
H. pylori-associated GA (evidence level: high quality; grade of 
recommendation: high; level of agreement: 100%).
We suggest that H. pylori eradication may be of some benefit 
to reduce the risk of developing gastric adenocarcinoma in 
those who already have H. pylori-associated GIM, dysplasia or 
cancer (evidence level: high quality; grade of recommendation: 
weak; level of agreement: 100%).
Although there is good evidence that H. pylori eradication 
reduces the subsequent risk of gastric adenocarcinoma develop-
ment, it has been hypothesised that there may be a ‘point of 
no return’ in the precancerous cascade. This question has been 
assessed in many studies and has been the topic of two recent 
independent systematic reviews and meta-analyses and most 
recently a large RCT.
Chen et al performed a meta-analysis of 10 studies from 
eight RCTs with a total of 7955 participants.104 These authors 
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divided participants into subgroups based on their baseline diag-
noses, comparing a group without GIM (normal, non-atrophic 
gastritis, GA) and a group with GIM (GIM or dysplasia). H. 
pylori treatment compared with controls significantly reduced 
the risk of gastric cancer, with a pooled RR of 0.64 (95% CI 
0.48 to 0.85). Subgroup analysis for patients with non-atrophic 
gastritis and GA yielded similar results (RR=0.25, 95% CI 0.08 
to 0.81). However, this difference was not seen in patients with 
GIM or dysplasia (RR=0.88, 95% CI 0.59 to 1.31). The authors 
concluded that H. pylori treatment no longer reduced the risk of 
gastric adenocarcinoma development once patients had devel-
oped GIM or dysplasia.
Rokkas et al105 recently published a second independent 
meta-analysis on this topic.105 They analysed 26 studies (10 RCTs 
and 16 cohort studies) and included 52 363 subjects. The risk 
of gastric adenocarcinoma among patients in whom H. pylori 
had been successfully eradicated was significantly lower than 
that among controls (pooled RRs (95% CI) 0.56 (0.48 to 0.66), 
Z=−7.27, p=0.00001). In patients with precancerous lesions, 
however, subgroup analyses showed that patients with non-atro-
phic or GA benefited from H. pylori eradication to decrease the 
risk of gastric cancer development, whereas those with GIM 
or dysplasia did not. In contrast to these data, a recent large, 
randomised, placebo-controlled trial demonstrated a significant 
reduction in metachronous gastric adenocarcinoma rates after 
endoscopic resection of intramucosal cancer and HGD in the H 
pylori eradication group (13.4% vs 7.9%; p=0.03).106 Further-
more, there appeared to be a reversal in the severity of both GA 
and GIM in the corpus, but not in the antrum.
Current high-quality data therefore suggest that while eradi-
cation of H. pylori reduces subsequent gastric adenocarcinoma 
risk in patients who have non-atrophic or GA, these benefits 
are not consistently maintained in patients who have developed 
GIM, dysplasia or cancer. The published meta-analyses did not, 
however, examine whether the histological type, severity and 
location of GIM or dysplasia influence this response to treat-
ment. Although early data do not consistently support the use 
of H. pylori eradication in patients who already have established 
intestinal metaplasia, dysplasia or cancer, the aforementioned 
RCT provides evidence to treat those with established cancer 
or HGD.
Although most of the published evidence is from the Far East, 
there is no compelling evidence to suggest that the fundamental 
process of gastric carcinogenesis differs according to geograph-
ical location. Published evidence suggests that H. pylori eradi-
cation appears to prevent gastric cancer development in some 
patients who have atrophic gastritis. Despite the lack of studies 
from the UK and Europe, H. pylori eradication is likely to 
benefit some European patients who have atrophic gastritis, and 
has a very low risk of causing serious adverse events. Further 
studies in European populations are needed to expand the pool 
of evidence that will influence this recommendation when these 
guidelines are revised.
The success of an H. pylori eradication strategy to try to 
prevent cancer development in patients who have premalignant 
gastric conditions will obviously be influenced by the success 
rate of the bacterial eradication regimen that is used. The choice 
of eradication regimen is beyond the scope of these guidelines, 
but its efficacy should be monitored. Regimens other than 
the classic triple therapy may need to be employed, particularly 
in geographical locations where the rates of H. pylori antibiotic 
resistance are known to be high.
In addition to the conventional Correa cascade of gastric 
carcinogenesis, there are other gastric conditions that are 
potentially associated with an increased risk of gastric cancer 
development—in particular, some gastric polyps.107 Although 
there is good evidence to suggest that H. pylori eradication 
leads to the regression of gastric hyperplastic polyps, no studies 
appear to have analysed whether this influences the subsequent 
risk of gastric adenocarcinoma.108–110 Studies on the effects of H. 
pylori eradication in patients with gastric adenomas are too small 
to draw any valid conclusions.111
biomarkers and gastric cancer
What biomarkers are useful in the management of these lesions?
Can they be applied to population screening, monitoring 
those at risk or those with known lesions?
Measurement of serum pepsinogen I and serum pepsinogen I/
II ratio alone or in combination with H. pylori serology, and/
or gastrin-17 can identify individuals with extensive atrophic 
gastritis (evidence level: low quality; grade of recommendation: 
weak; level of agreement: 93%).
We do not recommend the use of biomarkers as a screening tool 
in areas with a low incidence of gastric adenocarcinoma, such as 
the UK (evidence level: low quality; grade of recommendation: 
weak; level of agreement: 100%).
CAG, dysplasia and gastric adenocarcinoma
Pepsinogen I (PGI) is mainly secreted by chief and mucous neck 
cells in the fundic mucosa, while pepsinogen II (PGII) is also 
secreted by pyloric and duodenal Brunner’s glands. Approxi-
mately 1% of pepsinogens are found in the serum, with their 
serum level accepted as a marker for the morphological and 
functional status of the gastric mucosa.10 112 113 Serum PGI 
and PGII levels both increase in gastric mucosal inflammation; 
however, as GA develops and specialised cells are lost, PGI and 
PGII levels decrease, usually more marked in PGI, resulting in 
low serum PGI and a low PGI/II ratio.114
The combined use of serum PGI and PGI/II ratio measurements 
is an accepted useful biomarker for premalignant and malignant 
gastric lesions.112 Studies exploring their use as a population 
screening tool, where those with a positive pepsinogen result 
progress to endoscopic examination, have been shown to be 
acceptable in screening asymptomatic populations, with a good 
uptake of invitations for endoscopy—over 60%, in those with a 
positive pepsinogen result.115 116
biomarker detection of CAG, dysplasia and gastric cancer
Numerous studies across many different countries and popu-
lations have explored the use of serum pepsinogen testing for 
detection of CAG, dysplasia and gastric adenocarcinoma. The 
majority of these studies are from countries with a higher inci-
dence of these lesions than the UK. For countries with an inci-
dence of gastric adenocarcinoma similar to that of the UK, a 
study by Broutet et al in 2003 assessed serum pepsinogen testing 
across 14 European nations and determined that the PGI/II 
ratio may be of use as a screening test.112 117 118 However, in 
the majority of studies, the values used to define a positive 
pepsinogen test result and the study outcomes are reflective of 
populations that differ from the UK population. Additionally, 
many of these studies use differing cut-off values, which makes 
comparison difficult. However, the most frequently used values 
for these studies are a PGI <70 ng/mL and a PGI/II ratio ≤3.112 
Values can be affected by laboratory methodologies and popula-
tion settings, and therefore may require adjustment if applied to 
the UK population.
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A meta-analysis by Huang et al found that serum pepsinogen 
testing had a sensitivity and specificity of 69% and 73% for 
gastric cancer diagnosis and 69% and 88% for CAG diagnosis, 
respectively.112 This analysis included a study population of 
over 30 000 individuals, across 13 different countries and diag-
nosis confirmed with gastroscopy and biopsy. This is compa-
rable with the 2004 meta-analysis performed by Dinis-Ribeiro 
et al, using a cut-off value of PGI <50 and PGI/II ratio ≤3 for 
dysplasia detection, where sensitivity and specificity were 65% 
and 74–85%, respectively.117 This included a study population of 
approximately 300 000 patients. Finally, in a 2014 meta-analysis 
by Terasawa et al, a study population of approximately 32 000 
patients, in which individuals were prospectively followed up 
for between 3.9 and 14 years found that a positive pepsinogen 
test had a sensitivity of 57% and specificity of 76% for the devel-
opment of gastric adenocarcinoma.119
biomarker population screening
Although pepsinogen testing has been demonstrated as a useful 
tool for population screening in high-risk areas, its use in 
low-risk areas such as the UK has not been explored.116 119 120 In 
particular, one must consider whether the moderately effective 
sensitivities and specificities of pepsinogen testing are cost-ef-
fective for screening an asymptomatic population where the 
incidence of the disease is low. A 2015 study by Yeh et al used 
a mathematical simulation model to calculate the cost-effective-
ness of population screening strategies based on biomarker and 
endoscopic technologies in the low-risk US population (defined 
as an age-standardised rate (ASR) <10 per 100 000).113 This 
study found that although one-time serum pepsinogen testing at 
the age of 50 could prevent one in four cases of gastric adeno-
carcinoma among men, it was not of high value in improving 
cancer outcomes. However, targeting the high-risk group of 
male smokers over 50 years old could be a cost-effective way to 
reduce mortality from gastric adenocarcinoma.113 This screening 
model requires further exploration.
H. pylori serology has been studied extensively both as a 
population screening tool alone, as part of a ‘test and treat’ 
strategy and in conjunction with pepsinogen testing. While its 
use as a screening tool or in the ‘test and treat’ strategy may 
have advantages in high-incidence areas (defined as an ASR 
>20 per 100 000), the disadvantages, including low specificity 
and antibiotic resistance in low-risk populations, render its use 
redundant.121 The use of H. pylori serology in combination with 
pepsinogen is more accurate. In particular, the finding of nega-
tive serum anti-H. pylori IgG antibody and positive pepsinogen 
measurements suggests extensive GA, and thus these individuals 
are at highest risk of progression to cancer.10 121 The ABCD 
method for the detection of individuals with high gastric adeno-
carcinoma risk has been extensively investigated in high-risk 
populations. This method categorises patients tested for H. pylori 
serology (HP) and the ratios of serum PGI and PGII (sPG) into 
low risk (A: HP−, sPG−), moderate risk (B: HP+ and sPG−) 
and high risk (C: HP+ and sPG+; D: HP−, sPG+). Although 
in a 20-year prospective study the HRs for developing gastric 
adenocarcinoma were 15 for group D when compared with 
group A,122 further evidence is required to support the use of 
these approaches in a low-risk population.
GastroPanel combines PGI, PGII, gastrin-17 and H. pylori 
serology. A recent meta-analysis assessed the performance of 
this serum panel test for the diagnosis of CAG in 4241 subjects. 
The sensitivity for CAG was 74.7% (95% CI 62.0% to 84.3%) 
and the specificity was 95.6% (95% CI 92.6% to 97.4%). With 
a prevalence of CAG of 27% (median prevalence across the 
studies), the negative predictive value was 91% and the positive 
predictive value was 86%.123 Thus, although studies to date have 
shown promise, there is little evidence to support its use, with 
conflicting data on its efficacy.124–126
Finally, note is made of studies exploring the detection of 
volatile organic compounds in exhaled breath that are associated 
with the detection of gastric adenocarcinoma.127
Endoscopic diagnosis of premalignant or early malignant 
lesions of the stomach
Ensuring high-quality endoscopic evaluation
Outside the recommendations within the UK guidelines for 
quality endoscopy, are there further processes that are suggested 
for the detection and diagnosis of premalignant or early 
malignant lesions of the stomach? Is a station-based approach 
beneficial?
We recommend that patients at higher risk for gastric adeno-
carcinoma, including GA and GIM, should undergo a full system-
atic endoscopy protocol of the stomach with clear photographic 
documentation of gastric regions and pathology. We suggest a 
minimum examination time of 7 min (evidence level: moderate 
quality; grade of recommendation: strong; level of agreement: 
100%).
Endoscopy needs to be of high quality in order to detect 
dysplasia and early cancers, particularly in light of postendos-
copy gastric cancer rates of 11.3%.128 Recognising and targeting 
high-risk patients with GA and GIM may be the most effective 
means to improve gastric cancer detection, and possibly survival, 
in the UK. There are three basic principles, which are part of 
routine practice: cleaning of the gastric mucosa, adequate disten-
tion of the gastric wall by air insufflation and mapping the entire 
stomach.
Although there is little available evidence on the use of smooth 
muscle relaxants and mucosal cleaning techniques, the new BSG 
position statement on quality standards in upper gastrointes-
tinal endoscopy recommends ‘Adequate mucosal visualisation 
should be achieved by a combination of adequate air insuffla-
tion, aspiration and the use of mucosal cleansing techniques’.129 
We recommend that this guidance is also applied to inspection 
of GA and GIM.
There is also a paucity of data on the assessment of a complete 
endoscopic procedure. In particular, no clinical trials have 
directly clarified key performance indicators or quality assur-
ance (QA) for improving gastric cancer detection, and no studies 
have explored the outcomes of systematic screening protocols 
for the stomach. The European Society of Gastrointestinal 
Endoscopy (ESGE) performance measures for upper GI endos-
copy have suggested that the inspection of the oesophagus, 
stomach and duodenum should last at least 7 min from intuba-
tion to extubation.130 This statement was based on a retrospec-
tive cohort study by Teh et al, which aimed to determine the 
diagnostic yield for early neoplastic lesions in the stomach.131 
After evaluating 837 endoscopies of symptomatic patients with 
no history of gastric cancer, they found that a ‘slow’ endosco-
pist (>7 min examination) was twice as likely to detect high-risk 
gastric lesions, defined as biopsy evidence of GA, GIM, gastric 
dysplasia or cancer, and three times as likely to detect a case of 
dysplasia or cancer compared with a ‘fast’ endoscopist (<7 min 
examination).131 132
Photographic documentation might be an indirect quality 
indicator. Endoscopists with longer procedure times, who take 
more than four pictures, detect more pathology.132 The ESGE 
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has recommended five areas in the stomach should be photo-
graphically documented, including the cardia and fundus in 
inversion, corpus in forward view including lesser curvature, 
corpus in retroflex view including greater curvature, angulus in 
partial inversion, and antrum. Images may be used in case discus-
sions, patient management and compared with histology to aid 
learning.
In Japan, a systematic screening protocol for the upper 
GI tract has been developed, although this is considered too 
complex for routine clinical practice.133 This was revised by the 
Japanese Society of Gastroenterological Cancer Screening to a 
simplified, but still elaborate protocol.134 Yao has more recently 
simplified this further to propose as a minimum required quality 
standard a ‘systematic screening protocol for the stomach’.135 
This is a station-based approach whereby each area of the 
stomach is viewed and photographed in either a clockwise 
or counterclockwise manner. The 22 pictures are arranged 
according to the order of the procedure. Additional pictures are 
taken of lesions (Figure 2). A recent study from China found 
that training including a systematic inspection protocol with 20 
photos increased the detection of early gastric cancer from 0.2% 
to 2.3%.136
An e-learning module has been developed to teach endosco-
pists how to diagnose early gastric cancer based on the charac-
terisation of gastritis-like lesions, ulcerative lesions and polypoid 
lesions, the so-called GUP system.137 138 The GUP system has been 
evaluated in an RCT involving 332 endoscopists in 27 countries, 
with a higher mean improvement rate in the e-learning group 
than that of the non-e-learning group.138 A further study clearly 
demonstrated the efficacy of an e-learning system in improving 
endoscopists’ capabilities to diagnose early gastric cancer using 
magnification-narrow band imaging.139 Such validated training 
modules may be incorporated into any future quality improve-
ment (QI) programmes aimed at improving diagnosis of gastric 
cancer.
We recommend that when either GA or GIM is recognised 
on WLE, a full systematic endoscopic examination of the whole 
stomach is performed, taking no less than 7 min, with full photo-
graphic documentation of antrum, pylorus, incisura, lesser curve, 
greater curve, fundus and cardia. For patients without known 
risk factors for gastric cancer, we recommend a standardised 
high-quality endoscopy as defined in the UK quality in upper 
gastrointestinal endoscopy position statement.
Optical endoscopic diagnosis of the premalignant or early malignant 
stomach
How does one identify premalignant or early malignant lesions 
and ensure accurate documentation when reporting? Are there 
mucosal features that identify these lesions (including recog-
nising the atrophic border)?
What histopathogical and imaging modalities are suggested 
for the staging of glandular premalignant and early gastric malig-
nant lesions of the stomach?
GA and GIM may be detectable by WLE; however, the accuracy 
is poor. Therefore, we do not recommend establishing a diagnosis 
or risk stratification using WLE alone (evidence level: moderate 
quality; grade of recommendation: strong; level of agreement: 
93%).
We recommend IEE as the best imaging modality to accurately 
detect and risk-stratify GA and GIM (evidence level: moderate 
quality; grade of recommendation: strong; level of agreement: 
100%).
We recommend that endoscopic appearances on WLE sugges-
tive of GA or GIM require escalation to high-resolution IEE and, 
where available, magnification endoscopy (Evidence level: low 
quality; grade of recommendation: strong; level of agreement: 
100%).
We recommend that the location and extent of GA and GIM 
should be clearly documented with photographic evidence. Endo-
scopic grading should be documented as distal gastric (affecting 
antrum or incisura—low risk) or proximal gastric (affecting the 
corpus with or without the antrum and incisura—high risk) 
(evidence level: low quality; grade of recommendation: strong; 
level of agreement: 93%).
We recommend that endoscopic appearances on WLE of gastric 
dysplasia and early gastric cancer (differences in colour, loss of 
vascularity, slight elevation or depression, nodularity, thickening, 
and abnormal convergence or flattening of folds) require esca-
lation to IEE and, where available, magnification endoscopy 
(evidence level: low quality; grade of recommendation: strong; 
level of agreement: 100%).
We recommend IEE as the best imaging modality to accurately 
diagnose and stage gastric dysplasia and early gastric cancer 
(evidence level: moderate quality; grade of recommendation: 
strong; level of agreement: 100%).
Endoscopic detection and staging of GA, GIM and dysplasia is 
achievable with high-resolution WLE but improved with image 
enhancement and magnification endoscopy. The white light, 
image-enhanced and magnification appearances of the different 
mucosal patterns within the stomach are described below, 
covering the normal antrum and corpus, as well as GA and GIM.
normal gastric appearances
White light endoscopy
Typically, the surface of the normal corpus, when the stomach 
is empty and not distended, is almost invariably in folds, also 
called rugae, which vary in size depending on the degree of 
insufflation during the endoscopic assessment. In contrast, the 
surface of the normal fundus and antrum is smooth. The colour 
of the normal gastric mucosa, as indeed of the whole GI tract, 
is velvety, glossy dark rose or red with a regular arrangement 
of the collecting venules, usually visible as red spidery vessels 
Figure 2 Systematic screening protocol for the stomach. This is a 
station-based approach whereby each area of the stomach is viewed 
and photographed in either a clockwise or counterclockwise manner. 
The 22 pictures are arranged according to the order of the procedure. 
Q, quadrant; L, lesser curvature; A, anterior wall; G, greater curvature; P, 
posterior wall; SSS, systematic screening protocol for the somach. 
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in the normal corpus.140–143 The presence of these collecting 
venules is characteristic of a normal stomach without H. pylori 
(sensitivity 93%, specificity 48%).140 144 145 With current white 
light, high-resolution endoscopes, the round ‘pit patterns’ of the 
corpus and elongated ‘pit patterns’ of the antrum can be seen 
without magnification or enhancement (Figure 3Di).
Magnification and enhanced endoscopy
The two key features that characterise the gastric mucosa on 
magnifying endoscopy include the surface structure and vascular 
architecture.
Essentially, the corpus mucosa has straight or tubular glands 
with round ‘crypt openings’.146 These dark round pits are 
surrounded by the lighter coloured marginal crypt epithelia 
(MCE), then the darker circular subepithelial capillary network. 
This structure forms the typical foveolar type pattern, where 
dark areas (capillaries) surround light areas (glands).147–149 These 
appearances correspond with the tubular gland structure of the 
corpus mucosa histologically (Figure 3B & C). In narrow band 
imaging (NBI), the pattern ‘regular vessels with circular mucosa’ 
is associated with normal histology (accuracy 83%; 95% CI 75% 
to 90%).150
In contrast to the corpus, the glands in the antrum are oblique 
and branching and the dark ‘pit openings’ are grooved. The 
light-coloured ridged or villiform epithelium (MCE) surrounds 
the dark subepithelial capillary network, which can be seen as 
coiled vessels (Figure 3Aii Aiii). This appearance is termed the 
‘groove-type pattern’.147 148 These appearances correspond with 
the papillary surface structure of the antral mucosa histologically 
(Figure 3E & f).
Chronic h. pylori gastritis
A number of endoscopic features are suggestive of chronic H. 
pylori gastritis, including the absence of collecting venules, antral 
nodularity, enlarged gastric folds, enlargement and destruction 
of the gastric glands, sticky tenacious adherent mucous, turbid 
gastric juice, and xanthomas.140–142 Loss of collecting venules 
and capillary vascular structure was correlated with chronic 
inflammation and activity. With progression of mucosal atrophy, 
irregular collecting venules become visible.151
Gastric atrophy
Four principal endoscopic features of GA are described by 
Nakayama et al, Uedo et al and Yao et al152–154: pallor, loss of 
gastric folds, prominence of the vessels and the atrophic border 
(Figure 4). Increased visibility of the vascular network showed 
a sensitivity of 48% and a specificity of 87%, while the loss of 
gastric folds has a sensitivity of 67% and specificity of 85%.155
Long-term cohort studies suggest that the Kimura-Takemoto 
classification is a useful risk stratification assessment tool to 
predict gastric adenocarcinoma development.26 31 156 Essen-
tially this tool uses the extent of the atrophic border (the border 
between the pale atrophy and normal red-coloured stomach) to 
stage the extent of GA (Figure 4). In a cross-sectional cluster 
sampling historical study between the UK and Japan, endoscopic 
grading was shown to be comparable to histopathology and 
correctly predict histopathological atrophy with few false-neg-
ative results.157 158 This work needs further confirmation in a 
larger setting outside of Japan. The Kimura-Takemoto classifica-
tion has been simplified to a modified staging system involving 
the antrum only (antral), antrum to incisura (antral dominant), 
antrum to lesser curve (corpus dominant), and antrum, lesser 
curve and greater curve (pan-atrophy). This staging system inte-
grates the Sydney biopsy system discussed later (Figure 5). The 
GDG agreed that the extent of GA and GIM should be strati-
fied as low risk (involving the antrum and incisura) or high risk 
(involving the corpus and the antrum/incisura or the corpus 
alone).
Gastric intestinal metaplasia
White light endoscopy
GIM typically appears as small grey-white slightly elevated 
plaques surrounded by mixed patchy pink and pale areas 
of mucosa causing an irregular uneven surface (figure 6A). 
Figure 3 Normal gastric corpus and antrum mucosal surface pattern 
with white light, enhanced and magnification endoscopy. The round ‘pit 
patterns’ of the corpus (Ai) and elongated ‘pit patterns’ of the antrum 
(Di) can be seen without magnification or enhancement. In the corpus 
(Ai), the red collecting venules (CV) are evident as well as the round 
dark red crypt openings (CO). The vascular anatomy becomes more 
pronounced with NBI (Aii & Dii). The visible anatomical components 
seen on magnification NBI include the dark brown ‘crypt openings’ 
(CO), the dark brown sub-epithelial capillary network (SECN), and the 
light brown marginal crypt epithelia (MCE). The corpus mucosa has 
dark round ‘crypt openings’, surrounded by the lighter MCE, followed 
by the darker circular SECN (Aii & Aiii). In contrast, the dark, oblique 
‘crypt openings’ in the antrum are grooved so the light coloured ridged 
or villiform epithelium (MCE) surrounds the dark SECN, termed the 
‘groove type pattern’ (Dii & Diii). The corresponding histopathological 
architecture can be seen in the corpus (B and C) and in the antrum (E 
and F).
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Mottled patchy erythema has also been positively associ-
ated with GIM.159 However, diagnosis using standard endos-
copy alone (without high-resolution or enhanced imaging) is 
unreliable.160–165
magnification and iEE
As patches of GIM expand, the straight/tubular glands of the 
corpus elongate to a ‘groove-type pattern’ similar to that of 
the antrum or villiform pattern of the intestine (figure 6C 
D). Although these changes can easily be distinguished from 
the normal mucosal background in the corpus both with 
high-resolution white light and enhanced endoscopy, GIM in 
the antrum is more difficult to characterise as the pre-existent 
mucosal architecture is quite similar and also appears oblique 
and grooved.148 166 Additional features of GIM include the 
light blue crest (LBC) and the marginal turbid band (MTB)167 
and the white opaque substance (lipid droplets) obscuring the 
subepithelial capillaries.168 The LBC is a fine, blue-white line 
on the crest of the mucosal surface seen with NBI enhance-
ment and is a highly specific sign of the presence of GIM166 169 
(figure 6E F). The MTB is a white turbid band on the mucosal 
surface. It is suggested that the MTB may represent a sign 
of early GIM, whereas the LBC appears with progression to 
severe GIM, although whether this is reproducible remains 
uncertain.
optimal techniques for the detection and classification of GA 
and Gim
Most studies have demonstrated improved accuracy of enhanced 
and magnification imaging in the classification and detec-
tion of GA, GIM, dysplasia and cancer, in comparison with 
WLE.150 162 163 165 170 171 An overview of enhanced imaging 
studies with various modalities and their performance character-
istics is provided in table 4.
A simplified classification system using NBI without magnifi-
cation by Pimentel-Nunes et al has been shown to be accurate 
and reliable for the diagnosis of GIM and dysplasia.150 In the 
validation study a tubulovillous mucosal pattern was associated 
with GIM (accuracy 84%). Irregular vessels and mucosal pattern 
were associated with dysplasia (accuracy 95%). The LBC finding 
was moderately reliable (k=0.49), but very specific (96%) for 
GIM. In a recent study by Kanemitsu et al,168 the sensitivity and 
specificity of LBC for histologically diagnosed intestinal meta-
plasia were 62.5% and 93.8%, respectively. The sensitivity and 
specificity of white opaque substance were 50.0% and 100.0% 
(95% CI 85.0% to 100.0%), respectively. The combination of 
LBC and white opaque substance improved the overall sensi-
tivity up to 87% and 93.8%.
A second prospective multicentre study compared WLE 
with WLE plus NBI.162 NBI demonstrated a high concordance 
with histopathological diagnosis, superior to standard WLE. 
However, it is important to note that this study assessed WLE 
plus NBI, rather than NBI alone, and although high-resolu-
tion WLE had a good overall sensitivity of 85% for all pathology, 
this decreased to 53% for the detection of GIM. NBI versus WLE 
Figure 4 Chronic atrophic gastritis (CAG) and the atrophic border on 
white light and image enhanced endoscopy. There are four principle 
endoscopic features of CAG: palor (A, B, C, D and E), loss of gastric folds 
(A, B, C, D and E), prominence of the vessels (A, B, C and D) and the 
atrophic border (A and B). The paler areas of atrophy are also clear on 
image enhancement (F).
Figure 5 The Integrated and Modified Kimura & Sydney Biopsy 
System. The modified Kimura staging system divides the extent of 
atrophy into antrum only (antral), antrum to incisura (antral dominant), 
antrum to lesser curve (corpus dominant), and antrum, lesser curve and 
greater curve (pan-atrophy). This system integrates Sydney protocol 
biopsies which should be taken from the antrum (site 1 and 2), incisura 
(site 3), lesser curve (site 4) and greater curve (site 5). The anatomical 
CAG boundaries and biopsy sites can be seen in the splayed (A) and 
cross-sectional cartoon (B) of the stomach. The biopsy sites defined in 
the endoscopic retroflexed (C) and forward view (D).
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increased the sensitivity for the diagnosis of intestinal metaplasia 
significantly (87% vs 53%; p<0.001) and for the diagnosis of 
dysplasia (92% vs 74%). This study suggests that WLE alone 
is therefore not sufficiently accurate for GIM detection. Similar 
comparative results have been demonstrated in a recent prospec-
tive blinded trial.165
The sensitivity and specificity of WLE for the histological 
diagnosis of GA were reported to be 61.5% and 57.7%, respec-
tively, in the antrum, and 46.8% and 76.4%, respectively, in the 
body of the stomach.170
Compared with WLE, NBI combined with magni-
fying endoscopy can also effectively diagnose early gastric 
adenocarcinoma.171
Thus, in summary, the GDG agreed that WLE alone was 
not sufficiently accurate to reliably diagnose GA or GIM, and 
enhanced optical techniques should be used for diagnosis and 
staging.
A scale for endoscopic staging of GIM using NBI was created 
and returned an area under the curve (AUC) of 0.98 for WLE 
followed by NBI for diffuse GIM.162 This was externally vali-
dated by the same group, and for a diagnosis of OLGIM III/
VI the AUC was 0.96 (95% CI 0.93 to 0.98). This endoscopic 
grading of GIM was 89% sensitive and 95% specific for a risk 
stratification of moderate to severe GIM if a cut-off score 
of >4 was used.172 On this basis, it could be argued that endo-
scopic staging with high-resolution WLE plus NBI is sufficiently 
accurate for diagnosis and staging. This is an area of active 
future research.
Gastric dysplasia and early gastric cancer
Detection of gastric dysplasia and early gastric cancer is noto-
riously difficult due to the often only subtle findings and the 
lack of well-defined endoscopic appearances under white light 
inspection. Features commonly described, but not exhaustive, 
include differences in colour (ie, more red or pale), loss of vascu-
larity, slight elevation or depression, nodularity, thickening, and 
abnormal convergence or flattening of folds.173 174
Therefore, optimal clearing of mucous and secretions is essen-
tial to allow for continuous and meticulous search of areas with 
features different from the surrounding mucosa.175 176
Recourse to chromoendoscopy with indigo carmine solu-
tion (0.2%) or virtual chromoendoscopy (NBI, flexible spec-
tral imaging colour enhancement (FICE), i-Scan, blue laser 
imaging) is commonly advocated to enhance contrast and 
visualisation of areas of concern or mucosal abnormalities. 
Areas of dysplasia may present throughout the stomach, with a 
slight predominance in the antrum and along the lesser curva-
ture, and can vary in size from a few millimetres to several 
centimetres.
Gastric dysplasia can be morphologically classified into adeno-
matous (intestinal), which includes adenomatous polyps; foveolar 
(gastric); and hybrid type.47 177 Compared with the adenomatous 
type, the foveolar type appears to be more commonly associ-
ated with HGD.47 178 Endoscopically, these lesions are usually 
detected as 0–Is, 0–IIa or 0–IIc types according to the Paris clas-
sification of superficial neoplastic lesions.175
Adenomatous dysplasia is more likely to occur in the gastric 
body and lesser curvature of the stomach, whereas foveolar 
dysplasia is more typically located in the gastric antrum and 
incisura angularis. In addition, foveolar-type lesions are smaller, 
often reddish in colour and present as flat or depressed areas 
more frequently than the adenomatous type.47
Biopsy strategy for diagnosis and risk stratification of the 
premalignant stomach
What biopsy strategy should be adopted for the sampling and 
reporting of the premalignant and early malignant stomach?
Should all those undergoing routine endoscopy be biopsied or 
are there groups to target?
We recommend that patients with image-enhanced features 
of CAG should undergo biopsies for confirmation of endoscopic 
diagnosis; biopsies are directed at mucosal sites within Sydney 
protocol areas where enhanced imaging discloses GIM. Biopsy 
samples should be collected in separate containers and labelled 
as either ‘directed’ or ‘random’ to corroborate endoscopic staging 
assessment (evidence level: low quality; grade of recommenda-
tion: strong; level of agreement: 93%).
We suggest that a baseline endoscopy with biopsies should 
be considered in individuals aged ≥50 years, with laboratory 
evidence of pernicious anaemia, defined by vitamin B12 deficiency 
Figure 6 Gastric intestinal metaplasia under white light, image 
enhanced and magnification endoscopy. Intestinal metaplasia typically 
appears as small grey-white slightly elevated plaques surrounded 
by mixed patchy pink and pale areas of mucosa causing an irregular 
uneven surface (A). These appearances are more evident with image 
enhancement (B). Corpus GIM can be distinguished from the normal 
straight/tubular glands of the corpus by a ‘groove type pattern’ similar 
to that of the antrum or villiform pattern of the intestine and may be 
appreciated with higher resolution technology on white light endoscopy 
(C). GIM in the antrum is more difficult to characterize as the normal 
glands are oblique. Additional features of GIM to aid diagnosis in the 
antrum include the light blue crest (LBC) and the marginal turbid band 
(MTB) (D). The LBC is a fine, blue-white line on the crest of the epithelial 
surface seen with NBI enhancement (Fine arrows in D). The MTD can be 
seen between the broad arrows. The numerous goblet cells characterise 
GIM (E & F).
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and either positive gastric parietal cell or intrinsic factor anti-
bodies. As GA affects the corpus in pernicious anaemia, biopsies 
should be taken from the greater and lesser curves (evidence level: 
low quality; grade of recommendation: weak; level of agree-
ment: 93%).
Biopsies should be undertaken in patients with endoscopic 
suspicion of GA, GIM or early neoplasia.
Current surveillance protocols stipulate random biopsies in 
specified locations according to the updated Sydney protocol 
(Figure 5). However, random sampling does not reliably foster 
correlation of endoscopic and histopathological findings and 
carries a risk of sampling error. By contrast, ‘directed’ biop-
sies of mucosal foci suspicious for GIM in areas of the updated 
Sydney protocol will drive quality control and ultimately propel 
endoscopy-led staging and risk stratification. This targeted 
biopsy strategy links endoscopic GIM detection with the well-es-
tablished OLGIM histopathological classification scheme. The 
aforementioned numerical endoscopic classification system 
for staging of GIM has been shown to correlate strongly with 
OLGIM and with the extent of GIM,150 further supporting this 
change in practice. The GDG did not agree on whether OLGA 
or OLGIM should be routinely used, principally because there is 
insufficient expertise or capacity for this to be routinely under-
taken. Individual units, however, may choose to adopt this risk 
stratification system.
survEillAnCE
Should individuals with gastric premalignant lesions undergo 
surveillance?
We recommend endoscopic surveillance every 3 years should 
be offered to patients diagnosed with extensive GA or GIM, 
defined as that affecting the antrum and body (evidence level: 
low quality; grade of recommendation: strong; level of agree-
ment: 100%).
We do not recommend surveillance in patients with GA or GIM 
limited just to the gastric antrum; unless there are additional 
risk factors such as a strong family history of gastric cancer or 
persistent H. pylori infection, then we suggest 3-yearly surveil-
lance (evidence level: low quality; grade of recommendation: 
strong; level of agreement: 93%).
We recommend that patients with non-visible LGD should 
undergo an immediate second endoscopy with enhanced imaging 
and extensive biopsy sampling, followed by a repeat endos-
copy within 1 year if no visible neoplasia is detected. If there is 
persistent, non-visible LGD, endoscopy should be repeated annu-
ally thereafter (evidence level: low quality; grade of recommen-
dation: strong; level of agreement: 100%).
We recommend that patients with non-visible HGD should 
undergo an immediate second endoscopy with enhanced imaging 
and extensive biopsy sampling. We recommend ongoing surveil-
lance at 6-monthly intervals for persistent, non-visible HGD. 
HGD should be discussed at the regional upper GI cancer 
MDT and referred to a clinician with the appropriate expertise 
(evidence level: low quality; grade of recommendation: strong; 
level of agreement: 100%).
surveillance of CAG
As the neoplastic cascade follows a multistep process from H. 
pylori-associated gastritis through GA and GIM to dysplasia,179 
it follows that surveillance of a high-risk population may lead to 
the detection of early gastric cancer. Furthermore, the evolution 
of endoscopic techniques such as ESD, with 5-year disease-free A
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survival rates of 99%,180 further supports the detection of early 
gastric cancer through surveillance.
Several factors influence the risk of progression to cancer, 
including the extent of atrophy and GIM and a family history 
of gastric cancer. A strong family history is defined as those 
with a first-degree relative or two or more second-degree family 
members with histologically proven gastric adenocarcinoma. 
Those at the highest risk with GIM in the antrum and corpus 
have a 9.8% cumulative 5-year incidence of cancer.26
Outcomes of endoscopic surveillance of premalignant conditions
No randomised controlled studies on the benefit of GIM surveil-
lance have been carried out. There are, however, observational 
data. A small UK study assessed the effect of endoscopic surveil-
lance of patients with GIM (specifically type III, incomplete 
GIM) every 6–12 months over a 12-year period. Of the 26 
patients surveyed, 11 developed gastric adenocarcinoma, which 
was limited to the mucosa or submucosa at the time of detection. 
Although four patients were lost to follow-up, in comparison 
with the unit as a whole, the proportion of early cancers was 
much greater in those patients surveilled.181
In a second study 166 patients with GIM, dysplasia, GA, ulcers 
or polyps were surveyed over 10 years and compared with 1753 
open-access endoscopy patients. Compared with the open-ac-
cess group, there were more stage I/II cancers (76% vs 23%) 
and an improved 5-year survival (50% vs 10%) in the surveil-
lance group. Of the patients surveilled, 93 had GIM, of whom 
10 developed gastric adenocarcinoma. In patients with GA and 
GIM, the risk of malignancy was 11%.182 Both the aforemen-
tioned studies, however, were conducted before the advent of 
high-resolution endoscopy and IEE, which makes it difficult to 
extrapolate to current practice.
A northern European study in low-incidence gastric cancer 
areas surveyed 279 patients with GA, GIM or dysplasia over a 
mean period of 57 months. Of these, 1.4% (four patients) were 
diagnosed with HGD or gastric cancer, of whom two were 
successfully treated by ESD and two by gastrectomy. All four 
patients whose disease progressed had extensive GIM as defined 
by the OLGIM stage. None of those with limited GA or GIM 
progressed. The overall risk of neoplastic progression was 0.3% 
a year.183
A number of studies have evaluated surveillance in pernicious 
anaemia and body-predominant atrophic gastritis; however, only 
one study has demonstrated the development of gastric cancer in 
2 of 56 patients at the time of a surveillance endoscopy, 3 years 
after the initial endoscopy.
The MAPS guidelines published in 2012 recommend that 
patients with extensive GA and/or extensive GIM should be 
offered endoscopic surveillance every 3 years.10 MAPS also 
recommends that patients with mild to moderate atrophy or 
GIM limited to the antrum do not need follow-up.
Cost-effectiveness of endoscopic surveillance of premalignant 
conditions
Early studies examining the cost-effectiveness of CAG surveil-
lance have obtained conflicting results, which is partly due to 
the widely ranging variation in prevalence and progression 
to cancer. Modelling undertaken by Yeh et al in 2010 in a US 
population found surveillance to be cost-effective for men over 
50 years with dysplasia treated by EMR with annual surveillance 
(cost per quality-adjusted life-year (QALY) was US$39 800), 
although for 10-yearly surveillance in those with any GIM 
(US$544 500).184 A more recent cost-utility economic analysis 
in a European population aged between 50 and 75 years aimed 
to assess the cost-effectiveness of endoscopic screening of the 
premalignant stomach using Markov modelling.185 The primary 
outcome was the incremental cost-effectiveness ratio (ICER) of 
a 3-yearly endoscopic surveillance versus no surveillance. Endo-
scopic surveillance every 3 years provided an ICER of €18 336, 
well below the adopted threshold of €36 575 corresponding to 
the proposed guideline limit of US$50 000. Moreover, robust-
ness analysis showed that in 78% of examined scenarios the 
model was cost-effective. Three-yearly surveillance was found to 
be more cost-effective than 5–10 yearly strategies. Two further 
studies from low to intermediate risk populations in Singapore 
using Markov modelling and cost-utility analysis found 1-yearly 
and 2-yearly surveillance were cost-effective, although 3-yearly 
intervals were not analysed.186 187 In conclusion, recent cost-ef-
fectiveness models support surveillance in CAG in populations 
at low to intermediate risk between 1-yearly and 3-yearly. These 
models did not investigate those with extensive CAG, where the 
risk of progression is greater and thus the cost-effectiveness is 
likely to be superior.
As the cancer risk of focal intestinal metaplasia of the cardia 
is poorly defined and appears much lower than short-segment 
Barrett’s oesophagus we do not recommend surveillance in this 
group.43
summary
Although there is a lack of randomised data on the survival 
benefits of surveillance for GIM, there is moderate evidence 
demonstrating progression of premalignant conditions, partic-
ularly extensive GIM, to gastric adenocarcinoma, and evolving 
data from surveillance studies. The cost-effectiveness data are 
also compelling. We do accept, however, as with surveillance 
of Barrett’s oesophagus, that surveillance of GA and GIM will 
remain controversial. We recommend a surveillance interval of 
3 years for those patients with extensive GA or GIM defined 
as that affecting the antrum and body. However, surveillance 
may not be appropriate for all patients with extensive atrophy 
and GIM, particularly the very elderly and those with multiple 
comorbidities where the benefit of surveillance may be offset by 
the risks of diagnostic endoscopy. For those with GA or GIM 
limited to the antrum, but with additional risk factors such as 
a family history of gastric adenocarcinoma and persistent H. 
pylori infection, we also recommend a surveillance interval of 
3 years. Persistent H. pylori infection is defined as that refractory 
to treatment. We also suggest, where possible, as with Barrett’s 
oesophagus surveillance, that endoscopy is undertaken on a 
dedicated screening list. The remit of these guidelines do not 
cover the management of HDGC.63
Surveillance of dysplasia
Although the risk of progression of dysplasia to gastric adeno-
carcinoma varies between studies, it is clear that HGD confers 
a greater risk of progression than LGD. Of patients with HGD, 
30% to 85% progress to cancer with follow-up periods of 
up to 5 years with an estimated annual incidence of 6%.25 44 
The overall risk of malignancy for LGD (combining mild and 
moderate dysplasia, as described in earlier classification systems) 
varies from 0% to 33% over follow-up periods of up to 
66 months.188–194 Two observational studies have shown progres-
sion rates of between 3% and 9%.190 191
Dysplasia in random biopsies also appears to increase the risk 
of cancer, possibly by as much as 6% a year.15 25 It is important 
to note that in those patients found to have incidental HGD 
 o
n
 24 July 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-318126 on 5 July 2019. Downloaded from 
20 Banks M, et al. Gut 2019;0:1–31. doi:10.1136/gutjnl-2018-318126
Guidelines
or cancer by random biopsies on the index endoscopy, 80% 
will have a detectable lesion by virtual chromoendoscopy.195 A 
finding of gastric dysplasia also carries a high risk of synchro-
nous gastric adenocarcinoma, with rates as high as 30% in some 
studies.196
The histopathological biopsy diagnosis may not be represen-
tative of the final histopathological grade on excision. This has 
been described in a meta-analysis of 16 studies including over 
3000 patients. Of patients initially diagnosed with LGD on 
biopsy, 25% were subsequently diagnosed with more advanced 
lesions after endoscopic resection.197 Of these, 16.7% were HGD 
and 6.9% were invasive lesions. A Korean series demonstrated 
a similar upgrade of diagnosis from LGD in 18.7% of cases.198 
Thus, the rate of underdiagnosis is not insignificant. These data, 
however, are discordant with the lower documented progression 
rates in larger series of up to 9%. The authors found that lesion 
size >2 cm, surface depression, absence of whitish discoloura-
tion, the presence of spontaneous bleeding and nodularity on 
endoscopic examination were the major risk factors associated 
with a higher histopathological grade on excision.197 198 In those 
patients who undergo surveillance, repeat or multiple biopsies 
appear to not substantially improve the accuracy of the initial 
diagnosis.199 200
Cases that are indefinite for dysplasia may also be under-
staged or overstaged, with up to 25% upstaged to dysplasia or 
cancer.201 202 We therefore recommend that patients who are 
indefinite for dysplasia are reviewed by an expert pathologist 
and undergo a repeat procedure with image enhancement.
Based on the current evidence, there are clear grounds to 
support the endoscopic resection of visible LGD and HGD, 
providing that the risk of endoscopic resection is justifiable 
for health reasons and is the preference of the patient. We suggest 
surveillance for HGD and LGD only if resection is not possible or 
appropriate, or if the dysplasia is not visible, or is the preference 
of the patient. For patients with LGD undergoing surveillance, 
we recommend surveillance intervals of 1 year with high-quality 
systematic endoscopy. If biopsies are negative for dysplasia after 
three consecutive endoscopies, then consider 3-yearly surveillance. 
For those with HGD undergoing surveillance, we recommend 
a repeat high-quality endoscopy, repeated 6-monthly thereafter. 
All visible dysplasia should be resected where appropriate. There 
are no cost-effectiveness studies on surveillance of either HGD 
or LGD, and it is unclear for how long surveillance should be 
continued. For those patients found to have non-visible dysplasia 
on random biopsies, we suggest an immediate systematic endos-
copy with enhanced imaging, if necessary in an expert centre.
Surveillance after EMR and ESD for dysplasia and early gastric 
cancer
The risk of neoplastic synchronous or metachronous lesions as 
well as recurrence after gastric ESD or EMR is high and varies 
between 10% and 20%.203–206 Therefore endoscopic surveillance 
is necessary. This will allow further diagnosis of early neoplastic 
lesions, which can then be removed endoscopically. Few data on 
the follow-up interval are available; however, most recurrences 
occur within the first year after resection.203 207–210 We suggest 
therefore that a follow-up endoscopy is undertaken 6 months 
after ESD or EMR of neoplasia, and if no lesions are identified, 
annually thereafter. This is in line with the Japanese and ESGE 
guidelines.211–213
Treatment: endoscopic therapy
What lesions are amenable to endoscopic removal?
How should these lesions be removed?
Are there criteria on histopathological assessment that deter-
mine prognosis and follow-up?
We recommend that all gastric dysplasia and early gastric 
adenocarcinoma should be resected en bloc (an EMR technique 
can achieve en bloc excision for lesions ≤10 mm in size, but only 
an ESD technique can ensure en bloc excision for lesions >10 mm 
in size) (evidence level: high quality; grade of recommendation: 
strong; level of agreement: 100%).
We recommend that complete (R0) endoscopic resection of 
gastric dysplasia and early gastric adenocarcinoma with the 
following features should be considered as curative:
1. LGD.
2. HGD.
3. Well or moderately differentiated intramucosal adenocarcino-
ma, irrespective of size and without ulceration.
4. Well or moderately differentiated intramucosal adenocarcino-
ma, <3.0 cm in size if ulcerated.
5. Well or moderately differentiated submucosal adenocarci-
noma, <3.0 cm in size, with superficial submucosal inva-
sion (Sm1; <500 μm submucosal invasion as measured in a 
straight line from the deepest fibre of the muscularis muco-
sae).
6. Poorly differentiated intramucosal adenocarcinoma, ≤2.0 cm 
in size (evidence level: moderate quality; grade of recom-
mendation: strong; level of agreement: 93%).
The histopathological features of early gastric adenocarcinoma 
associated with a higher risk of LNM after endoscopic resection 
include the following:
1. Poorly differentiated submucosal cancer, irrespective of inva-
sion depth below muscularis mucosae.
2. Signet ring cancer.
3. Lymphovascular invasion.
4. Depth of submucosal invasion ≥500 μm as measured in a 
straight line from the deepest fibre of the muscularis muco-
sae (evidence level: moderate quality; grade of recommenda-
tion: strong; level of agreement: 93%).
We suggest that, where possible, all cases considered for resec-
tion should be discussed in an MDT with the appropriate exper-
tise, including pathologists and therapeutic endoscopists. When 
there is no local expertise, patients should be referred to an 
expert centre. Before any therapeutic procedure is undertaken, 
the risks and benefits of endoscopic resection and surgery should 
be discussed with the patient to aid their decision-making.
These recommendations apply to the intestinal type of gastric 
cancer as defined by the Lauren classification.214 215 Diffuse-type 
adenocarcinoma carries a worse prognosis than the intestinal 
type, which appears to be independent of the T and N stage.215
The risk of LNM underpins endoluminal therapy for early 
gastric adenocarcinoma. This risk has to be weighed against 
the significant risk of morbidity and mortality following 
surgical resection. Endoscopic resection has become the 
preferred organ-preserving treatment for superficial gastric 
neoplastic lesions because of the low risk of LNM that these 
lesions portend. In a large series from the Far East, Gotoda et 
al reviewed the prevalence of LNM in 5265 gastrectomy speci-
mens. On multivariate analysis they found that none of the 979 
non-ulcerated lesions had LNM. Additionally, they found that 
none of the 145 well or moderately differentiated adenocarci-
nomas measuring <30 mm, those with submucosal invasion of 
<500 μm (Sm1), and those without lymphovascular invasion 
showed LNM.216 This supported the initial Japanese guide-
lines on the indication criteria for endoscopic resection of early 
gastric adenocarcinoma, which included intestinal-type adeno-
carcinoma, endoscopically diagnosed intramucosal cancer, lesion 
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size of ≤20 mm and non-ulcerated lesions.212 In a second large 
series, Hirasawa et al reviewed 3843 patients who underwent 
gastrectomy with lymph node dissection for poorly differenti-
ated adenocarcinoma. On multivariate analysis they found that 
lesion size of >20 mm, lymphovascular invasion and submucosal 
involvement were independent risk factors for LNM.217
Overall the two large series on surgically resected early gastric 
cancer demonstrate that the risk of LNM of superficial lesions is 
small (<1%) if the following criteria are met:
1. Well or moderately differentiated intramucosal adenocarci-
noma, irrespective of size and without ulceration.
2. Well or moderately differentiated intramucosal adenocarci-
noma, ≤3.0 cm in size if ulcerated.
3. Well or moderately differentiated submucosal adenocarci-
noma, <3.0 cm in size, with superficial submucosal inva-
sion (Sm1; <500 μm submucosal invasion as measured in a 
straight line from the deepest fibre of the muscularis muco-
sae).
4. Poorly differentiated intramucosal adenocarcinoma, <2.0 cm 
in size.
This led to the adoption of the expanded indications for 
ESD of early gastric cancer. The expanded criteria, however, 
should not be taken as absolute, particularly where the balance 
between risk and benefit of surgery is less clear. The original 
definition of early gastric cancer was defined in 1971 by the 
Japanese Society of Gastroenterology and Endoscopy as a carci-
noma limited to the mucosa and/or submucosa regardless of the 
lymph node status. This has recently fuelled much controversy 
as the survival of early gastric cancer is closely associated with 
the risk of LNM. We have therefore adopted the definition of 
adenocarcinoma limited to the mucosa and superficial submu-
cosa (Sm1; <500 μm), as that amenable to endoscopic resection.
Two recent series, one from the Far East and one from the 
West, assessed the outcomes of the extended indications. The 
series by Hasuike et al included 470 lesions, of which 466 
(99.1%) were resected en bloc and the curative resection rate 
was 67.4%.218 A similar Western series reported that en bloc 
resection was achieved in 81 of 91 lesions (89.0%) and curative 
resection was achieved in 67 of 91 lesions (73.6%).219 The risk 
of perforation in both series was reported to be up to 2.6%. 
However, the risk of delayed bleeding was lower in the Western 
series (2.2% compared with 6.2%). The higher curative resec-
tion and lower delayed bleeding rate in the Western series are 
encouraging, although the number of treated lesions was smaller.
Patient selection is key to achieving favourable outcomes 
with ESD for early gastric cancer. Patients who do not meet the 
expanded criteria for a curative outcome following gastric ESD 
are referred for radical surgery. In a multicentre retrospective 
study, Hatta et al developed a risk scoring system using multi-
variate logistic regression analysis of 1101 patients who had 
undergone radical surgery after failing to meet the criteria for 
curative endoscopic resection of early gastric cancer.220 They 
then validated the scoring system in a further 905 patients. They 
showed that the scoring system known as ‘eCura system’ (table 5) 
predicted cancer-specific survival in this cohort of patients. This 
scoring system is promising but will require further validation in 
other centres.
EMR (cap-assisted) was the initial technique used to resect 
superficial gastric neoplasia. However, this technique is unable 
to effectively resect lesions larger than 10 mm en bloc. In a 
recent meta-analysis comparing the efficacy of gastric ESD and 
EMR, the en bloc and R0 resection rates of EMR were found to 
be 51.7% and 42.4%, respectively.221 This, in turn, is associated 
with local recurrence rates as high as 30%.180 203 207 222–225 In 
a subgroup analysis of lesions smaller than 10–15 mm, it was 
noted that there was no difference in survival regardless of the 
endoscopic resection technique.
ESD was a technique developed to overcome the shortcom-
ings of gastric EMR, enabling the en bloc resection of lesions 
>10 mm. In a large series from the Far East of 1033 early gastric 
cancer lesions, Oda et al reported an en bloc resection and R0 
resection rate of 98% and 93%, respectively.226 Three meta-anal-
yses comparing the outcomes of EMR and ESD showed that ESD 
achieved higher en bloc resection rates (92% vs 52%; OR=9.69, 
95% CI 7.74 to 12.13), histopathologically complete resection 
rates (82% vs 42%; OR=5.66, 95% CI 2.92 to 10.96) and 
lower recurrence rates (1% vs 6%; OR=0.10, 95% CI 0.06 to 
0.18).221 227 228
The current Japanese Gastroenterological Endoscopy Society 
and ESGE guidelines recommend ESD as the preferred treat-
ment for most superficial gastric neoplastic lesions.211 229 
However, ESD is a technique that is in its infancy in the West, 
and the complication rates during early adoption can be high. 
In one European series of 75 patients who underwent gastric 
ESD, en bloc resection was achieved in 85.3% and R0 resec-
tion in 84.0%. However, the complication rate which included 
delayed bleeding and perforation was as high as 24%.230 Finally, 
it should be noted that signet ring cancer is not currently recom-
mended for endoscopic resection. However, prospective data 
will soon be published on the treatment of these lesions with 
ESD if they are <20 mm, which may alter this management 
strategy.
In summary we recommend, where appropriate, endoscopic 
resection as first-line treatment for all early gastric neoplasia in 
line with the Japanese extended indications, favouring ESD over 
EMR for larger lesions owing to the superior R0 resection rate. 
Surgery should be undertaken only when endoscopic resection is 
not considered curative or is the preferred patient option.
Treatment: pharmacological
Is there a role for other pharmacological therapies for example, 
COX inhibitors and antioxidants?
We do not recommend the use of NSAIDs or COX-2 inhibitors 
to reduce the risk of progression of premalignant lesions of the 
stomach (evidence level: moderate; grade of recommendation: 
strong; level of agreement: 100%).
We do not recommend the use of antioxidants as a means to 
reduce the prevalence of premalignant gastric lesions (evidence 
level: moderate; grade of recommendation: strong; level of 
agreement: 100%).
Table 5 eCura system
Weighted scores for risk factors
risk factors Points
Lymphatic invasion 3
Lesion size >30 mm 1
Positive vertical margin 1
Venous invasion 1
Submucosal invasion ≥500 μm 1
lymph node metastasis 
(lnm) risk groups Points risk of lnm (%)
Cancer-specific 
5-year survival (%)
Low 0–1 2.5 99.6
Intermediate 2–4 6.7 96.0
High 5–7 22.7 90.1
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NSAIDs, aspirin and COX-2 inhibitors
There are numerous examples of chronic inflammatory condi-
tions that predispose to cancer development. Meta-analyses and 
retrospective studies have demonstrated that there is a lower 
incidence of gastric cancer associated with regular, long-term use 
of NSAIDs, including aspirin.231–233 These are thought to reduce 
carcinogenesis by inhibiting cancer-associated prostaglandins, 
cytokines and angiogenic factors. However, their use has been 
limited by their other GI side effects, and there are few good-
quality, prospective trials to determine whether they can prevent 
the progression of premalignant gastric lesions.
Thus, attention has turned to COX-2 inhibitors, with trials 
particularly focusing on the use of rofecoxib, etodolac and 
celecoxib. However, there is limited evidence to support their 
use because of low-quality studies performed in heterogeneous 
populations in countries with a high incidence of gastric cancer. 
One placebo-controlled randomised control trial has been 
carried out, which explored the use of rofecoxib in reversing 
GIM in those cleared of H. pylori. It showed that there was no 
evidence that rofecoxib causes a regression in GIM over a 2-year 
period.234 Among the low-quality trials, a study using etodolac 
for patients who underwent endoscopic early cancer resection 
found a higher rate of metachronous cancer lesions in those 
treated with the COX-2 inhibitor.235 Only celecoxib has been 
suggested to provoke regression of gastric premalignant lesions; 
however, in general, these trials are limited to small patient 
numbers over short periods of time.236–238 A large Swedish popu-
lation-based, case–control study comparing 567 incident cases of 
gastric cancer and 1165 controls found that aspirin users had a 
moderately reduced risk of cardia and non-cardia gastric cancer 
(OR=0.7; 95% CI 0.6 to 1.0), although NSAID use had no 
protective effect in this study.239 A recent literature review of 24 
studies suggested that both aspirin and NSAIDs reduce the risk 
of gastric cancer with an RR of 0.7 (95% CI 0.62 to 0.80) and 
0.86 (95% CI 0.80 to 0.94), respectively.240 The dose–response 
analysis indicated that the risk decreased by 11% and 5% for 
2 years after a dose increment for both.
Further work is undoubtedly required to study the poten-
tial of celecoxib, aspirin and NSAIDs in the chemoprevention 
of premalignant gastric lesions—in particular, in well-designed, 
randomised, long-term follow-up trials in populations who have 
a low incidence of gastric cancer. Any benefit must be weighed 
against the known GI side effects of aspirin and NSAIDs.
Antioxidants
A limited number of trials have explored the use of antiox-
idants for chemoprevention of gastric premalignant lesions. 
Three studies have been performed, all in populations with a 
high incidence of gastric cancer and with generally disappointing 
results. Correa et al demonstrated some benefit for histopatho-
logical outcome at 6 years following ascorbic acid and β-carotene 
use, but this improvement was lost after 12 years.241 The other 
two studies did not show any benefit of using antioxidants in 
preventing the progression or causing regression of premalig-
nant gastric lesions.242 243
Endoscopic screening for gastric adenocarcinoma
Is there evidence to support the introduction of a population 
screening programme for glandular gastric cancer?
We suggest endoscopic screening should be considered in indi-
viduals aged ≥50 years with multiple risk factors for gastric adeno-
carcinoma (male, smokers, pernicious anaemia)—in particular, 
in those with a first-degree relative with gastric cancer (evidence 
level: low quality; grade of recommendation: weak; level of 
agreement: 100%).
We do not recommend endoscopic screening for gastric adeno-
carcinoma in the UK population (evidence level: low quality; 
grade of recommendation: strong; level of agreement: 100%).
Evidence for the effectiveness of endoscopic screening for 
prevention of gastric cancer has been gathered from studies 
conducted in high-risk populations (defined as an ASR >20 per 
100 000); in Japan and Korea (29.9 and 41.3, respectively).244 
These include five cohort studies and three case–control studies. 
Although there are no randomised control trials, the results 
of the available studies suggest a reduction in mortality from 
gastric cancer in screened populations. In the more recent 
regional Japanese cohort studies, there was a reduction in gastric 
cancer mortality (calculated as the standardised mortality ratio 
or adjusted RR) of 57% and 67% after a 5-year and 6-year 
follow-up.245–247 The earlier cohort studies from Japan and 
China were less convincing but were limited by a broad age 
distribution and poorly matched cohorts.248 249 The results of 
the case–control studies were equally variable with a reduction 
in gastric cancer mortality of between 20% and 80% in high-
risk populations in Japan and South Korea.250 251 Based on 
these results, the authors recommended endoscopic screening in 
regions with a high incidence of gastric cancer.
The test characteristics of endoscopic screening have been 
described in four studies. Hosokawa et al found the sensitivity 
of endoscopy to be 78% after comparing the gastric cancer 
incidence in those screened from a cancer registry.252 Similar 
sensitivities of 69% and 89% have been found across other 
cancer registries in Japan and South Korea.253–255 In the South 
Korean study the gastric cancer detection rate was 2.61 per 1000 
screening endoscopies, with a specificity of 96%.253
There have been two studies in low-incidence regions (defined 
as an ASR <10 per 100 000), such as the USA (3.9 per 100 000), 
assessing the cost-effectiveness of endoscopic screening. The cost 
of a single-screening endoscopy at the age of 50 in the general 
population was US$115 664 per QALY, suggesting that endo-
scopic screening was not cost-effective.184 256 Cost-effectiveness 
analyses in higher risk areas have demonstrated an ICER of 
US$44 098 and US$25 949 per QALY for annual and biannual 
screening endoscopy, respectively.186 In a study in Taiwan where 
patients at the age of 50 who had low levels of pepsinogen-I 
(<30 ng/mL) were offered endoscopy, the ICER was US$29 741 
per life-year gained.257
A Markov model of screening in an intermediate-risk popu-
lation (ASR of >10 and <20 per 100 000 population) for 
ages 50–75 years found that upper endoscopy combined with 
screening colonoscopy (every 10 or 5 years) had an ICER of 
€15 407/QALY and €30 908/QALY, respectively.258 Standalone 
endoscopic screening (every 5 years) had an ICER of €70 693/
QALY and pepsinogen screening an ICER of €143 344/QALY. 
This work suggests that endoscopic gastric cancer screening in 
conjunction with a scheduled colonoscopy may be cost-effec-
tive in countries with intermediate gastric adenocarcinoma risk 
such as in Eastern Europe or Portugal. These results imply that 
resources allocated to endoscopic colorectal cancer screening 
programmes could be used to provide gastric cancer screening, 
both for detection of high-risk individuals with extensive prema-
lignant conditions and patients with early gastric cancer.
Although there is insufficient evidence to support screening in 
low-risk populations, a recent study by Shawihdi and colleagues 
demonstrated wide variations in rates of elective gastroscopy 
within general practice populations. They showed that patients 
with oesophagogastric cancer belonging to practices with low 
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rates of gastroscopy were at increased risk of poor outcome. 
However, if the low referral practices increased to the mid-re-
ferral range, the crude cost per life-year saved for a hypothet-
ical scenario is £140 000, well above a suggested threshold of 
£25 000. Therefore despite the poorer outcomes, given the high 
costs, primary care physicians should follow a restrictive referral 
practice.259
A recent retrospective nationwide Taiwanese propensi-
ty-matched cohort study evaluating the impact of non-screening 
gastroscopy on gastric cancer-related mortality found that 
patients with gastric cancer who had undergone gastroscopy in 
the 5 years before the diagnosis of gastric cancer had a better 
survival than patients who had never undergone a gastroscopy 
or whose last gastroscopy was more than 5 years before the 
diagnosis. The authors found that gastric cancer was detected 
at an earlier stage in patients who had recently undergone 
endoscopy. The risk of gastric cancer in this study population 
is low to moderate. This is the first study showing a signifi-
cant survival advantage of recent endoscopy in patients with 
gastric cancer in a region of low to moderate gastric cancer 
incidence.260
There are factors apart from the premalignant stomach that 
confer a greater risk of gastric adenocarcinoma as described 
in the 'Risk factors for gastric adenocarcinoma' section. These 
include family history, particularly those with first-degree rela-
tives, pernicious anaemia with an annual incidence of 0.27% in 
unsubstantiated cases, older age, male and smoking. Ethnicity 
is also related to an increased risk, but this may be due to a 
higher prevalence of H. pylori. In individuals within low-risk 
populations who have additional risk factors as described above, 
screening endoscopy may be of value.
In summary, we suggest that only those with multiple risk 
factors for gastric cancer are considered for screening gastros-
copy from the age of 50. If the gastroscopy results are normal, 
then we would not recommend any further screening. Where 
CAG is diagnosed, this guideline should be followed.
diagnosis and management of epithelial gastric polyps
What are epithelial gastric polyps and how should they be 
managed ?
We recommend that the number of gastric polyps (or estimated 
number), location of polyps and size of largest polyp should be 
clearly documented (evidence level: low quality; grade of recom-
mendation: strong; level of agreement: 100%).
We recommend that gastric polyps other than FGPs should be 
biopsied for histopathological assessment (evidence level: low 
quality; grade of recommendation: strong; level of agreement: 
100%).
We recommend that photographic documentation should be 
undertaken for all polyps or representative polyps, if numerous 
(evidence level: low quality; grade of recommendation: strong; 
level of agreement: 100%).
We recommend that if adenomas or hyperplastic polyps 
are present, the background mucosa should be endoscopically 
assessed for GA, GIM, H. pylori and synchronous neoplasia 
(evidence level: moderate quality; grade of recommendation: 
strong; level of agreement: 100%).
We recommend that all adenomas should be resected when clin-
ically appropriate and safe to do so (evidence level: low quality; 
grade of recommendation: strong; level of agreement: 100%).
We recommend that a follow-up gastroscopy should be 
performed at 12 months after complete endoscopic excision 
of adenomas, then ongoing surveillance gastroscopy annually 
thereafter, when appropriate (evidence level: low quality; grade 
of recommendation: strong; level of agreement: 93%).
We suggest that hyperplastic polyps >1 cm, pedunculated 
morphology and those causing symptoms (obstruction, bleeding) 
should be resected. If present, H. pylori should be eradicated 
before re-evaluation for endoscopic therapy (evidence level: low 
quality; grade of recommendation: weak; level of agreement: 
100%).
We suggest that enhanced endoscopic imaging is used to aid 
characterisation of gastric polyps when there is diagnostic uncer-
tainty following white light examination (evidence level: low 
quality; grade of recommendation: weak; level of agreement: 
93%).
The scope of the guidelines is restricted to epithelial polyps, 
and thus neuroendocrine tumours and subepithelial polyps have 
been excluded. Gastric epithelial polyps can be mainly classified 
as three types107: FGPs, hyperplastic polyps and adenomatous 
polyps.
Fundic gland polyps
FGPs are the most prevalent type of gastric polyps (13–77%).261 262 
They are typically multiple, small (<1 cm) and located in the 
fundus and corpus. At endoscopy they appear pale, smooth, 
glassy, and transparent or translucent (figure 7). Their colour is 
either lighter or the same colour as the surrounding mucosa. Lacy 
blood vessels are seen through the translucent surface and the 
surface shows a pattern of fine grey dots. On enhanced imaging 
such as NBI, FICE or i-Scan, the surface architecture becomes 
more prominent. FGPs are usually not associated with an 
increased risk of cancer, unless in the context of FAP syndrome. 
However, larger FGPs (>1 cm) have been shown to be dysplastic 
in 1.9% and contain focal cancer also in 1.9%. FGPs are associ-
ated with long-term PPI use and can spontaneously regress when 
PPIs are stopped.263 There is no association with background H. 
pylori infection or gastritis.
Figure 7 Fundic glandular and hyperplastic polyps. A) Fundic 
glandular polyps seen in the corpus and body. They are either lighter 
or the same colour as the surrounding mucosa. B) On near view, 
with image enhancement, lacy blood vessels are seen through the 
translucent surface and the surface shows a pattern of fine grey dots. 
C) Hyperplastic polyps are smooth, red buttered with whitish exudates 
(fibrin) and are dome shaped. The surface vascular pattern is more 
prominent on image enhancement (D).
 o
n
 24 July 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-318126 on 5 July 2019. Downloaded from 
24 Banks M, et al. Gut 2019;0:1–31. doi:10.1136/gutjnl-2018-318126
Guidelines
Management of FGPs
Number, location, morphology and the size of the largest polyp 
should be documented. Representative pictures of the polyps 
should be taken. Diagnosis is easily made from the endoscopic 
appearance, as described above, but biopsy confirmation should 
be sought when in doubt. Large numbers of polyps (>20), 
young age (<40 years), dysplastic appearing polyps (where the 
typical surface and vascular architecture alter particularly when 
irregular) and the presence of duodenal adenomas should lead 
to exclusion of FAP.107 FGPs do not require excision unless they 
have atypical features. Size of >1 cm, antral location, ulcer-
ation or an unusual appearance should question the diagnosis 
of FGP and lead to excision.264 Targeted biopsies should be 
taken where excision is not undertaken. Patients receiving 
long-term PPIs should be re-evaluated for appropriateness of 
the PPI, dose of PPI and alternative treatments.263 There is no 
role for surveillance gastroscopy for FGPs, except in the setting 
of FAP.107
hyperplastic polyps
Hyperplastic polyps constitute 18–70% of all gastric polyps, are 
usually single or few in number and are more frequently observed 
in the antrum or adjacent to ulcers, stomas and gastrectomy 
sites. They appear as smooth, red buttered with whitish exudates 
(fibrin) and are dome-shaped (figure 7). They are usually small 
(0.5–1.5 cm), but may be larger and present as lobulated and 
pedunculated masses covered with superficial erosions. They are 
typically associated with H. pylori gastritis (25%), GA and GIM. 
Regression generally occurs after eradication of H. pylori (up to 
70%).108
Gastric hyperplastic polyps can reveal dysplasia (1.9–19%) 
and malignant transformation (0.6–2.1%),265–267 especially 
when >1 cm and in the postgastrectomy stomach.267–270 A 
dysplastic hyperplastic polyp is associated with an increased risk 
of synchronous neoplastic lesions in the surrounding mucosa of 
approximately 6% of cases.271–277
Small, white and flat plaques in the fundus have the appear-
ance of hyperplastic polyps with a foveolar pit pattern, but are 
areas of focal foveolar hyperplasia or more specifically, hyper-
plasia of the foveolar epithelium.278 These have been described 
as multiple white flat lesions (MWFLs) and appear to be more 
prevalent in those taking PPIs. Histologically, the biopsy spec-
imens from the MWFLs included fundic gland parietal cell 
protrusions and oxyntic gland dilatations. There was no evidence 
of intestinal metaplasia.279
Management of hyperplastic polyps
Diagnosis of hyperplastic polyps and the absence of dysplasia 
should be confirmed by histology. The remainder of the stomach 
should be carefully evaluated for synchronous neoplasia, 
degree and extent of GA and H. pylori. H. pylori eradication 
should be considered in all cases before endoscopic resection as 
many polyps will regress, and a repeat endoscopy carried out 
3–6 months after eradication.108 Polyps of >1 cm, peduncu-
lated polyp morphology or symptomatic polyps (obstruction, 
bleeding) should be completely resected.268 280 Even when H. 
pylori is present, those polyps >3 cm should always be resected 
as the risk of dysplasia and cancer is high.267 280 Endoscopic 
surveillance is recommended to monitor the risk of further 
gastric neoplasia where there is evidence of dysplasia, GA or 
GIM. The endoscopic surveillance interval should be deter-
mined by the stage of CAG.
Adenomatous polyps
Adenomatous polyps are usually single (82%), small (<2 cm) 
and located in the antrum and incisura angularis. Endoscopically 
they have a velvety pink lobulated appearance and can be sessile 
or pedunculated. In Western countries their prevalence varies 
between 0.5% and 10%.264 281 They are normally associated with 
a background of GA and GIM. Coexistence of a synchronous 
gastric adenocarcinoma has been found in up to 30% of patients 
with an adenomatous polyp. Moreover, 50% of adenomatous 
polyps >2 cm contain foci of adenocarcinoma.196 282
Management of gastric adenomas
Gastric adenomas carry a significant risk of progression to 
cancer and should be resected where appropriate. Diagnosis 
of adenoma and degree of dysplasia should be histologically 
confirmed before treatment is undertaken. A careful evaluation 
of the stomach should be carried out to identify synchronous 
neoplasia (30%), GA and GIM. Endoscopic resection is the 
preferred mode of treatment. An en bloc excision with ESD is 
advisable for sessile polyps >15 mm211 as the possibility of inva-
sive neoplasia in the adenoma is high and ESD reduces the risk 
of recurrence compared with EMR. A follow-up gastroscopy 
should be performed at 6–12 months after endoscopic resection 
of adenomas. Patients with adenomas should continue to have 
surveillance gastroscopy at yearly intervals where appropriate, 
depending on the number of polyps, their size and the highest 
grade of dysplasia.
Optical diagnosis of gastric polyps
Optical enhancement with technology, including NBI (Olympus), 
i-Scan (Pentax) and FICE (Fujinon) with or without near focus 
or magnification allows interpretation of the mucosal surface 
architectural patterns and vasculature. FGPs are characterised by 
small round pits and a honeycomb microvascular pattern (sensi-
tivity 94.7%, specificity 97.4%), whereas hyperplastic polyps 
display prolonged or villous pits and a dense vascular pattern 
(sensitivity 93.6%, specificity 91.6%).283 The NBI features of 
gastric adenomas have not been well defined, although a paler 
colour relative to the background mucosa and a slit-like crypt 
opening and regular white opaque substance, which corresponds 
to absorbed subepithelial lipid droplets, are often observed. The 
brown colour on NBI is due to the subepithelial vessels, which 
are obscured by lipid droplets accumulated above the subepi-
thelial vessels. A tubular, villous or ridged mucosal structure is 
generally observed as with colonic adenomas.153 284 285
Based on the National Institute for Health and Care Excel-
lence classification validated for colon polyps, a modified NBI 
classification system has been recently proposed in a retrospec-
tive evaluation by two expert reviewers to reliably diagnose 
low-risk gastric polyps (FGPs or hyperplastic polyps <1 cm) with 
the aim of eliminating the need for biopsy.286
Relative to the background mucosa, polyps were divided in 
two groups:
1. Lighter or same colour.
2. Darker.
‘Lighter or same colour’ polyps were further subdivided 
according to their vascular network in:
a. Isolated vessels.
b. No vessels.
c. Brown vessels surrounding white structures.
Polyps with same or lighter colour and with no vessels or 
isolated lacy vessels were FGPs in 97–100%. Polyps lighter or 
similar in colour to the background mucosa with a homogeneous 
 o
n
 24 July 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-318126 on 5 July 2019. Downloaded from 
25Banks M, et al. Gut 2019;0:1–31. doi:10.1136/gutjnl-2018-318126
Guidelines
absence of surface pattern were FGPs in 94–100%. The sensi-
tivity and specificity for lacy vessels were 61–66% and 93–96%, 
respectively, for optical FGP diagnosis. If a lesion had either 
isolated lacy vessels or homogeneous absence of pattern, the 
negative predictive value for gastric adenoma or cancer was 
100%. The negative predictive value for colour the same or 
lighter than the background mucosa was 96–97%. Polyps with 
colour lighter or the same as the background mucosa, but >1 cm 
or showing brown vessels surrounding white structures, or those 
darker in colour, require biopsy. Although useful as a research 
algorithm for assisting decision-making, further studies and vali-
dation of this classification are required.
All polyps where the mucosal pattern is disorganised, irreg-
ular or absent (amorphous) are suspicious for neoplasia. Like-
wise, enhanced or irregular vascular patterns are suspicious for 
neoplasia, and targeted biopsies should be carried out.
In summary, IEE improves the visualisation of gastric polyps 
and allows the diagnosis of FGPs. Diagnosis of hyperplastic 
polyps and adenomas with IEE is less clear, but may aid in the 
diagnosis of HGD or cancer. We therefore have suggested that 
IEE is used in all polyps to aid diagnosis and direct biopsies.
It is important to emphasise that the evidence for the detection, 
characterisation and management of gastric polyps was gener-
ated using lower resolution endoscopes, and thus further studies 
are needed to investigate the accuracy of optical and targeted 
histological diagnosis with newer endoscopes. Currently, the 
evidence supports endoscopic resection rather than biopsy 
of many non-fundic glandular polyps given the likelihood of 
upstaging neoplasia.287 This is of particular importance given the 
risks of bleeding associated with gastric polypectomy.
EduCATion, AudiT, And bEnChmArks And rEsEArCh 
QuEsTions
Audit and benchmarks
The prevalence of GIM in patients undergoing endoscopy for 
dyspepsia is as high as 25% in European studies. The preva-
lence of GIM is influenced by ethnicity, infection rates with H. 
pylori, age and family history of gastric cancer. GIM is present 
in 100% of intestinal-type gastric cancer. Detection of GIM is 
therefore crucial as a first step in order to identify those at risk of 
gastric adenocarcinoma and may be an obvious benchmark as a 
quality standard for upper GI endoscopy. The prevalence of GA 
in Western populations is lower than GIM and varies from 0% 
to 8%, as previously described. We suggest a benchmark of 10% 
detection rate for GIM and/or GA in those patients undergoing 
investigation for upper GI symptoms.
Education
The miss rate for gastric cancer on endoscopy is high, and 
awareness of the endoscopic features of its precursors, GA and 
GIM, is low. We suggest that knowledge of these pathologies 
is incorporated into the new national gastroenterology curric-
ulum for higher training for gastroenterologists, surgeons and 
pathologists.
service and cost implications of the guidelines
An extensive service evaluation has not been conducted for this 
guideline. We have made an estimate of the likely additional work 
generated by their adoption. As discussed, in Western popula-
tions (Europe and USA) the overall prevalence of CAG in young 
men and women (<55 years) was 0–8.3%. In older age groups 
(>55 years), the prevalence was reported to be up to 13%20 and in 
the EUROGAST study <5%19 and 5.3% in those aged 55–64 years. 
Of the 1.7 million endoscopies performed each year in the UK, 
approximately 40% are upper GI procedures.288 Thus, in a unit 
performing a total of 10 000 procedures a year, 4000 will be upper 
GI endoscopies, of which approximately 200 patients will have 
CAG. Assuming endoscopic diagnostic accuracy of 100% and a 
CAG prevalence of 5%, this will give rise to 200 additional sets 
of Sydney biopsies, assuming the unit was not previously taking 
biopsy samples for CAG. This is likely to result in a repeat proce-
dure in a proportion of cases where IEE was not available during 
the initial endoscopy. There are no clear data to define the propor-
tion of CAG that extensively affects the stomach and therefore 
requires surveillance, but we have estimated this to be 40% of all 
CAG diagnosed based on our own experience. We estimate that 
there will be 130 patients per unit requiring surveillance endoscopy 
between 1 and 3 yearly.
Future research
This guideline aims to improve the standardisation of practice in 
the management of patients at risk of gastric adenocarcinoma. We 
envisage that improved endoscopic quality, and consequently the 
detection of CAG and early gastric neoplasia, with targeted surveil-
lance will improve the outcomes of gastric cancer. However, the 
effect of the guidelines on gastric cancer survival nationally is likely 
to be small, principally because only a small proportion of patients 
with gastric cancer will be detected by endoscopy at an early stage. 
Therefore, studies of cost-effective, non-invasive, population-based 
screening should be a research priority of the next 5–7 years. The 
other main priority is a measurable improvement in the quality of 
gastroscopy.
Quality standards (QA) and improvement (QI)
 ► We suggest that a QI bundle for upper GI endoscopy requires 
derivation and assessment as a priority for research in order 
to improve diagnostic rates of early gastric neoplasia and its 
precursors (GA and GIM).
 ► We suggest that quality indicators are required 
for systematic gastric surveillance endoscopy and 
photographic documentation.
Screening and surveillance
 ► We suggest pilot studies for non-invasive, population-based 
screening strategies for gastric cancer are a research priority.
 ► We suggest that a pilot study is required to assess the cost-ef-
fectiveness of endoscopic gastric cancer screening when 
combined with a screening colonoscopy.
 ► We suggest that further research is required to investigate the 
optimal surveillance strategy for CAG,
Diagnosis and staging
 ► We suggest that the accuracy and reproducibility of optical 
diagnosis and staging of GA and GIM need to be investi-
gated in a multicentre study.
 ► We suggest research to determine whether the severity and 
distribution of CAG categorised by OLGA and OLGIM 
accurately reflect cancer risk during follow-up.
 ► Cytosponge has been shown to detect cardia intestinal meta-
plasia,289 but more research is needed to see if this might be 
a tool to help identify cardia IM as a triage to endoscopy.
 ► We suggest that further research is required to investigate 
the risk of progression of histologically and serologically 
confirmed pernicious anaemia.
 ► We suggest that the natural history and risk of progression 
to cancer of visible and non-visible LGD requires further 
research. 
Prevalence
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 ► We suggest that further research is required to quantify more 
accurately the prevalence and extent of GIM in European 
endoscopy practice.
Planned review date
The guidelines should be considered for review in 5 years from 
the date of submission for publication, estimated to be November 
2023.
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